U.S. patent application number 12/436255 was filed with the patent office on 2009-08-27 for 1h-pyrimido[4,5-b]indole derivatives, their preparation and therapeutic use.
This patent application is currently assigned to SANOFI-AVENTIS. Invention is credited to Jacques FROISSANT, Frank MARGUET, Anne OLIVIER-BANDINI, Frederic PUECH.
Application Number | 20090215741 12/436255 |
Document ID | / |
Family ID | 35445724 |
Filed Date | 2009-08-27 |
United States Patent
Application |
20090215741 |
Kind Code |
A1 |
FROISSANT; Jacques ; et
al. |
August 27, 2009 |
1H-Pyrimido[4,5-b]indole Derivatives, Their Preparation and
Therapeutic Use
Abstract
The disclosure concerns compounds of general formula (I):
##STR00001## wherein n, X, Y, R.sub.1 and R.sub.2 are as defined
herein. The disclosure also concerns a method for preparing the
compounds and their therapeutic use.
Inventors: |
FROISSANT; Jacques;
(Brevainville, FR) ; MARGUET; Frank; (Verrieres Le
Buisson, FR) ; OLIVIER-BANDINI; Anne; (Paris, FR)
; PUECH; Frederic; (La Celle Saint Cloud, FR) |
Correspondence
Address: |
ANDREA Q. RYAN;SANOFI-AVENTIS U.S. LLC
1041 ROUTE 202-206, MAIL CODE: D303A
BRIDGEWATER
NJ
08807
US
|
Assignee: |
SANOFI-AVENTIS
Paris
FR
|
Family ID: |
35445724 |
Appl. No.: |
12/436255 |
Filed: |
May 6, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11873789 |
Oct 17, 2007 |
7547706 |
|
|
12436255 |
|
|
|
|
PCT/FR2006/000843 |
Apr 18, 2006 |
|
|
|
11873789 |
|
|
|
|
Current U.S.
Class: |
514/210.18 ;
514/232.8; 514/267; 544/115; 544/250 |
Current CPC
Class: |
A61P 25/02 20180101;
A61P 19/02 20180101; C07D 209/12 20130101; A61P 9/10 20180101; A61P
25/10 20180101; A61P 11/00 20180101; A61P 13/12 20180101; A61P
25/08 20180101; A61P 31/22 20180101; C07D 487/04 20130101; A61P
9/14 20180101; A61P 11/16 20180101; A61P 25/20 20180101; A61P 29/00
20180101; A61P 17/00 20180101; A61P 25/12 20180101; A61P 7/02
20180101; A61P 37/08 20180101; A61P 11/06 20180101; A61P 25/22
20180101; A61P 35/00 20180101; A61P 9/04 20180101; A61P 17/02
20180101; A61P 17/04 20180101; A61P 37/06 20180101; A61P 17/06
20180101; A61P 25/00 20180101 |
Class at
Publication: |
514/210.18 ;
544/250; 514/267; 514/232.8; 544/115 |
International
Class: |
A61K 31/519 20060101
A61K031/519; C07D 487/04 20060101 C07D487/04; A61K 31/5377 20060101
A61K031/5377 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 20, 2005 |
FR |
0503934 |
Claims
1. A compound of formula (III): ##STR00007## in which X represents
a hydrogen or halogen atom; R.sub.1 represents a hydrogen atom or a
(C.sub.1-C.sub.6)alkyl group; and R.sub.4 and R.sub.5 each
represent, independently of one another, a hydrogen atom or a
(C.sub.1-C.sub.6)alkyl group, or else R.sub.4 and R.sub.5 form,
with the nitrogen atom that they bear, an aziridinyl, azetidinyl,
pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or
piperazinyl, optionally subtituted by a (C.sub.1-C.sub.6)alkyl,
phenyl or heterocycle.
2. A method for the treatment of a disease in a patient, said
disease selected from the group consisting of traumatic or ischemic
neuropathy, spinal amyotrophy, amyotrophic lateral sclerosis,
cerebrovascular accident, cranial and medular trauma, multiple
sclerosis, Alzheimer's disease, Parkinson's disease, anxiety,
epilepsy and sleep disorder, comprising administering to said
patient a therapeutically effective amount of a compound of formula
(I) or a pharmaceutically acceptable salt thereof: ##STR00008## in
which: n represents the number 0 or 1; X represents a hydrogen or
halogen atom; Y represents an OR.sub.3 group or an NR.sub.4R.sub.5
group; R.sub.1 represents a hydrogen atom or a
(C.sub.1-C.sub.6)alkyl group; R.sub.2 represents a
(C.sub.1-C.sub.6)alkyl group, a phenyl or a monocyclic or bicyclic
heterocycle, said phenyl or heterocycle groups optionally bearing
one or more groups independently selected from halogen atoms,
(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxyl,
(C.sub.1-C.sub.6)alkoxy(C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.6)alkylamino(C.sub.1-C.sub.6)alkyl and
(C.sub.1-C.sub.6)dialkylamino(C.sub.1-C.sub.6)alkyl groups; R.sub.3
represents a hydrogen atom, a (C.sub.1-C.sub.6)alkyl group or a
benzyl; and R.sub.4 and R.sub.5 each represent, independently of
one another, a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group, or
else R.sub.4 and R.sub.5 form, with the nitrogen atom that they
bear, an aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl,
morpholinyl, thiomorpholinyl or piperazinyl, optionally substituted
by a (C.sub.1-C.sub.6)alkyl, phenyl or heterocycle.
3. The method according to claim 2, wherein: n represents the
number 0 or 1; X represents a hydrogen or halogen atom; Y
represents an OR.sub.3 group or an NR.sub.4R.sub.5 group; R.sub.1
represents a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group;
R.sub.2 represents a phenyl or a heterocycle chosen from pyridinyl,
pyrimidinyl, pyrazinyl or pyridazinyl, the phenyl or heterocycle
optionally bearing one or more groups independently selected from
halogen atoms, (C.sub.1-C.sub.6)alkyl and (C.sub.1-C.sub.6)alkoxyl
groups; R.sub.3 represents a hydrogen atom, a
(C.sub.1-C.sub.6)alkyl or a benzyl; and R.sub.4 and R.sub.5 each
represent, independently of one another, a hydrogen atom or a
(C.sub.1-C.sub.6)alkyl group, or else R.sub.4 and R.sub.5 form,
with the nitrogen atom that they bear, an aziridinyl, azetidinyl,
pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or
piperazinyl group, optionally substituted by a
(C.sub.1-C.sub.6)alkyl, phenyl or azetidinyl.
4. The method according to claim 2, wherein: n represents the
number 0 or 1; X represents a hydrogen or fluorine or chlorine
atom; Y represents a hydroxy, OCH.sub.3, O(CH.sub.2CH.sub.3),
N(CH.sub.3).sub.2, N(CH.sub.2CH.sub.3).sub.2, pyrrolidinyl,
piperidinyl, morpholinyl, (N-azetidinyl)piperidinyl or
N-methylpiperazinyl group; R.sub.1 represents a hydrogen atom, a
methyl or isobutyl group; and R.sub.2 represents a phenyl, a
methyl, isopropyl or cyclopropyl group or a heterocycle chosen from
pyridinyl, pyrazinyl, pyrimidinyl, thiazolyl, tetrahydroquinolinyl
or tetrahydropyranyl, the phenyl and heterocycle groups optionally
being substituted by one or more groups independently selected from
halogen groups, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxyl,
(C.sub.1-C.sub.6)alkoxy(C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.6)dialkylamino and (C.sub.1-C.sub.6)dialkyl-amino
(C.sub.1-C.sub.6)alkyl groups.
5. The method according to claim 2, wherein the compound is
selected from the group consisting of:
N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide;
7-chloro-N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide;
7-fluoro-N,N-9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide;
6-chloro-N,N-9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide;
7-chloro-N,N-dimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide;
7-chloro-N,N-diethyl-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxa-
mide;
7-chloro-9-methyl-2-phenyl-4-(pyrrolidin-1-ylcarbonyl)-9H-pyrimido[4-
,5-b]indole;
7-chloro-9-methyl-2-phenyl-4-(piperidin-1-ylcarbonyl)-9H-pyrimido[4,5-b]i-
ndole;
7-chloro-9-methyl-4-(morpholin-4-ylcarbonyl)-2-phenyl-9H-pyrimido[4-
,5-b]indole;
4-[(4-azetidin-1-yl)piperidin-1-ylcarbonyl]-7-chloro-9-methyl-2-phenyl-9H-
-pyrimido-[4,5-b]indole;
7-chloro-9-methyl-4-[(4-methylpiperazin-1-yl)carbonyl]-2-phenyl-9H-pyrimi-
do[4,5-b]indole;
6-chloro-N,N-9-trimethyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indole-4-carbox-
amide;
7-fluoro-N,N,9-trimethyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indole-4--
carboxamide;
7-chloro-9-methyl-2-pyridin-4-yl-4-(pyrrolidin-1-ylcarbonyl)-9H-pyrimido--
[4,5-b]indole;
7-chloro-N,N,9-trimethyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indole-4-carbox-
amide;
7-chloro-N,N,9-trimethyl-2-pyridin-3-yl-9H-pyrimido[4,5-b]indole-4--
carboxamide;
7-chloro-N,N-9-trimethyl-2-pyridin-2-yl-9H-pyrimido[4,5-b]indole-4-carbox-
amide
7-chloro-N,N-9-trimethyl-2-pyrazin-2-yl-9H-pyrimido[4,5-b]indole-4-c-
arboxamide;
2-(7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indol-4-yl)-N,N-dimethyla-
cetamide;
2-(6-chloro-9-methyl-2-phenyl-9H-pyrimido]4,5-b]indol-4-yl)-N,N--
dimethylacetamide;
2-(7-chloro-9-methyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indol-4-yl)-N,N-dim-
ethylacetamide;
2-(7-chloro-9-methyl-2-pyridin-3-yl-9H-pyrimido[4,5-b]indol-4-yl)-N,N-dim-
ethylacetamide;
N,N-dimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide; ethyl
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate;
methyl
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate;
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylic
acid;
7-chloro-N,N-9-trimethyl-2-(6-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indol-
e-4-carboxamide;
7-chloro-2-(6-methoxypyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indo-
le-4-carboxamide;
7-chloro-N,N-9-trimethyl-2-(2-methylpyridin-4-yl)-9H-pyrimido[4,5-b]indol-
e-4-carboxamide;
7-chloro-2-(2-methoxypyridin-4-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indo-
le-4-carboxamide;
7-chloro-9-isobutyl-N,N-dimethyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indole--
4-carboxamide;
7-chloro-2-cyclopropyl-N,N,9-trimethyl-9H-pyrimido[4,5-b]indole-4-carboxa-
mide;
7-chloro-N,N,2,9-tetramethyl-9H-pyrimido[4,5-b]indole-4-carboxamide;
7-chloro-2-isopropyl-N,N,9-trimethyl-9H-pyrimido[4,5-b]indole-4-carboxami-
de;
7-chloro-N,N,9-trimethyl-2-(tetrahydro-2H-pyran-4-yl)-9H-pyrimido[4,5--
b]indole-4-carboxamide;
7-chloro-2-{4-[(dimethylamino)methyl]phenyl}-N,N,9-trimethyl-9H-pyrimido[-
4,5-b]indole-4-carboxamide;
7-chloro-2-(6-chloropyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indol-
e-4-carboxamide;
7-chloro-N,N,9-trimethyl-2-[6-(trifluoromethyl)pyridin-3-yl]-9H-pyrimido[-
4,5-b]indole-4-carboxamide;
7-chloro-2-(6-ethoxypyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indol-
e-4-carboxamide;
7-chloro-2-(6-ethylpyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indole-
-4-carboxamide;
7-chloro-2-(5-ethylpyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indole-
-4-carboxamide;
7-chloro-N,N,9-trimethyl-2-(5-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indol-
e-4-carboxamide;
7-chloro-N,N,9-trimethyl-2-pyrimidin-5-yl-9H-pyrimido[4,5-b]indole-4-carb-
oxamide;
7-chloro-2-(5-methoxypyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,-
5-b]indole-4-carboxamide;
7-chloro-2-[6-(methoxymethyl)pyridin-3-yl]-N,N,9-trimethyl-9H-pyrimido[4,-
5-b]indole-4-carboxamide;
7-chloro-N,N,9-trimethyl-2-(2-methyl-1,3-thiazol-4-yl)-9H-pyrimido[4,5-b]-
indole-4-carboxamide;
7-chloro-2-{6-[(dimethylamino)methyl]pyridin-3-yl}-N,N,9-trimethyl-9H-pyr-
imido[4,5-b]indole-4-carboxamide;
7-chloro-2-(5,6-dimethylpyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]i-
ndole-4-carboxamide;
7-chloro-N,N,9-trimethyl-2-(5,6,7,8-tetrahydroquinolin-3-yl)9H-pyrimido[4-
,5-b]indole-4-carboxamide; and
7-chloro-2-(2,6-dimethylpyridin-4-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]i-
ndole-4-carboxamide; or a pharmaceutically acceptable salt
thereof.
6. The method according to claim 2, wherein the disease is selected
from traumatic or ischemic neuropathy, spinal amyotrophy and
amyotrophic lateral sclerosis.
7. The method according to claim 5, wherein the disease is selected
from traumatic or ischemic neuropathy, spinal amyotrophy and
amyotrophic lateral sclerosis.
8. The method according to claim 2, wherein the disease is
cerebrovascular accident.
9. The method according to claim 5, wherein the disease is
cerebrovascular accident.
10. The method according to claim 2, wherein the disease is cranial
and medular trauma.
11. The method according to claim 5, wherein the disease is cranial
and medular trauma.
12. The method according to claim 2, wherein the disease is
multiple sclerosis.
13. The method according to claim 5, wherein the disease is
multiple sclerosis.
14. The method according to claim 2, wherein the disease is chosen
from Alzheimer's disease or Parkinson's disease.
15. The method according to claim 5, wherein the disease is chosen
from Alzheimer's disease or Parkinson's disease.
16. The method according to claim 2, wherein the disease is
anxiety.
17. The method according to claim 5, wherein the disease is
anxiety.
18. The method according to claim 2, wherein the disease is chosen
from epilepsy or sleep disorder.
19. The method according to claim 5, wherein the disease is chosen
from epilepsy or sleep disorder.
Description
[0001] This application is a continuation of U.S. application Ser.
No. 11/873,789, filed Oct. 17, 2007, now allowed, which is a
continuation of International application No. PCT/FR2006/000,843,
filed Apr. 18, 2006, which are incorporated herein by reference in
their entirety; which claims the benefit of priority of French
Patent Application No. 05/03,934, filed Apr. 20, 2005.
[0002] One subject of the invention is 1H-pyrimido[4,5-b]indole
derivatives.
[0003] A first subject of the invention relates to the compounds
corresponding to the general formula (I) below.
[0004] Another subject of the invention relates to processes for
preparing compounds of general formula (I).
[0005] Another subject of the invention relates to compounds that
can be used, in particular, as intermediates for synthesizing
compounds of general formula (I).
[0006] Another subject of the invention relates to the uses of
compounds of general formula (I), especially in medications or in
pharmaceutical compositions.
[0007] The compounds of the invention correspond to the general
formula (I):
##STR00002##
in which: n represents the number 0 or 1; X represents a hydrogen
or halogen atom; Y represents an OR.sub.3 group or an
NR.sub.4R.sub.5 group; R.sub.1 represents a hydrogen atom or a
(C.sub.1-C.sub.6)alkyl group; R.sub.2 represents a
(C.sub.1-C.sub.6)alkyl group, a phenyl or a monocyclic or bicyclic
heterocycle, said phenyl or heterocycle groups possibly bearing one
or more halogen atoms and/or one or more (C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.6)alkoxyl, (C.sub.1-C.sub.6)alkoxy
(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkylamino
(C.sub.1-C.sub.6)alkyl or
(C.sub.1-C.sub.6)dialkylamino(C.sub.1-C.sub.6)alkyl groups; R.sub.3
represents a hydrogen atom, a (C.sub.1-C.sub.6)alkyl group or a
benzyl; and R.sub.4 and R.sub.5 each represent, independently of
one another, a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group, or
else R.sub.4 and R.sub.5 form, with the nitrogen atom that they
bear, an aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl,
morpholinyl, thiomorpholinyl or piperazinyl, optionally substituted
by a (C.sub.1-C.sub.6)alkyl, phenyl or heterocycle.
[0008] The compounds of formula (I) may comprise one or more
asymmetric carbon atoms. They may therefore exist in the form of
enantiomers or of diastereoisomers. These enantiomers,
diastereoisomers and also mixtures thereof, including racemic
mixtures, form part of the invention.
[0009] The compounds of formula (I) may exist in the base or acid
addition salt form. Such addition salts form part of the invention.
These salts are advantageously prepared with pharmaceutically
acceptable acids, but the salts of other acids that are useful, for
example, for purifying or isolating compounds of formula (I) also
form part of the invention.
[0010] The compounds of formula (I) may also exist in the form of
hydrates or solvates, namely in the form of associations or
combinations with one or more water molecules or with a solvent.
Such hydrates and solvates also form part of the invention.
[0011] Within the scope of the present invention: [0012] a halogen
atom represents a fluorine, a chlorine, a bromine or an iodine
atom; [0013] (C.sub.t-C.sub.Z) where t and z may take the values of
1 to 6, represents a carbon-based chain which may have from 1 to 6
carbon atoms; [0014] an alkyl group represents a saturated, linear,
branched or cyclic or combination thereof, aliphatic group
optionally substituted by one or more halogen atoms. As examples,
mention may be made of methyl, ethyl, propyl, isopropyl, butyl,
isobutyl, tert-butyl, pentyl, cyclopropyl, methylcyclopropyl,
cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl,
fluoromethyl or trifluoromethyl groups; [0015] an alkoxyl group
represents an oxygen atom substituted by an alkyl group where the
alkyl group is as defined previously. By way of example, mention
may be made of the methoxyl group; [0016] an alkylamino group
represents an amine substituted by an alkyl group where the alkyl
group is as defined previously. By way of example, mention may be
made of the methylamino group; [0017] an alkylaminoalkyl group
represents an alkyl group substituted by an alkylamino group. By
way of example, mention may be made of the (methylamino)methyl
group; [0018] a dialkylamino group represents an amine substituted
by two alkyl groups, where each alkyl group is as defined
previously. By way of example, mention may be made of the
dimethylamino group; [0019] a dialkylaminoalkyl group represents an
alkyl group substituted by a dialkylamino group. By way of example,
mention may be made of the (dimethylamino)methyl group; [0020] an
alkoxyalkyl group represents an alkyl group substituted by an
alkoxyl group. By way of examples, mention may be made of the
methoxymethyl, ethoxymethyl or methoxyethyl groups; and [0021] a
heterocycle represents a saturated, partially saturated or aromatic
ring with 4 to 12 chain members having at least one atom chosen
from O, S or N. As examples of monocyclic heterocycles, mention may
be made of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,
thiazolyl, furanyl, thiophenyl or tetrahydropyranyl groups. As
examples of bicyclic heterocycles, mention may be made of the
quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl,
quinoxalinyl, quinoazolinyl, phthalazinyl, cinnolinyl,
benzothiazolyl, benzofuranyl or benzothiophenyl groups.
[0022] A first subgroup of compounds of general formula (I) is
composed of compounds for which:
n represents the number 0 or 1; X represents a hydrogen or halogen
atom; Y represents an OR.sub.3 group or an NR.sub.4R.sub.5 group;
R.sub.1 represents a hydrogen atom or a (C.sub.1-C.sub.6)alkyl
group; R.sub.2 represents a phenyl or a heterocycle of pyridinyl,
pyrimidinyl, pyrazinyl or pyridazinyl type, the phenyl or the
heterocycle possibly bearing one or more halogen atoms and/or one
or more (C.sub.1-C.sub.6)alkyl or (C.sub.1-C.sub.6)alkoxyl groups;
R.sub.3 represents a hydrogen, a (C.sub.1-C.sub.6)alkyl or a
benzyl; and R.sub.4 and R.sub.5 each represent, each independently
of one another, a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group,
or else R.sub.4 and R.sub.5 form, with the nitrogen atom that they
bear, an aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl,
morpholinyl, thiomorpholinyl or piperazinyl group, optionally
substituted by a (C.sub.1-C.sub.6)alkyl, phenyl or azetidinyl.
[0023] A second subgroup of compounds of general formula (I) is
composed of compounds for which:
n represents the number 0 or 1; and/or X represents a hydrogen or
halogen atom, more particularly a chlorine or fluorine; and/or Y
represents an OR.sub.3 group or an NR.sub.4R.sub.5 group; and/or
R.sub.1 represents a hydrogen atom or a (C.sub.1-C.sub.6)alkyl
group, more particularly a methyl; and/or R.sub.2 represents a
phenyl or a heterocycle of pyridinyl or pyrazinyl type, the phenyl
or the heterocycle possibly bearing one or more
(C.sub.1-C.sub.6)alkyl groups, more particularly methyl, or
(C.sub.1-C.sub.6)alkoxyl groups, more particularly methoxy; and/or
R.sub.3 represents a hydrogen or a (C.sub.1-C.sub.6)alkyl, more
particularly a methyl or an ethyl; and/or R.sub.4 and R.sub.5 each
represent, each independently of one another, a
(C.sub.1-C.sub.6)alkyl group, more particularly a methyl or an
ethyl, or else R.sub.4 and R.sub.5 form, with the nitrogen atom
that they bear, a pyrrolidinyl, piperidinyl, morpholinyl or
piperazinyl group, optionally substituted by a
(C.sub.1-C.sub.6)alkyl, more particularly methyl, or an
azetidinyl.
[0024] A third subgroup of compounds of general formula (I) is
composed of the compounds for which:
n represents the number 0 or 1; X represents a hydrogen or fluorine
or chlorine atom; Y represents a hydroxy, OCH.sub.3,
O(CH.sub.2CH.sub.3), N(CH.sub.3).sub.2, N(CH.sub.2CH.sub.3).sub.2,
pyrrolidinyl, piperidinyl, morpholinyl, (N-azetidinyl)piperidinyl
or N-methylpiperazinyl group; R.sub.1 represents a hydrogen atom, a
methyl or isobutyl group; and R.sub.2 represents a phenyl, a
methyl, isopropyl or cyclopropyl group or a heterocycle of
pyridinyl, pyrazinyl, pyrimidinyl, thiazolyl, tetrahydroquinolinyl
or tetrahydropyranyl type, the phenyl and heterocycle groups
possibly optionally being substituted by one or more halogen groups
and/or one or more (C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.6)alkoxyl,
(C.sub.1-C.sub.6)alkoxy(C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.6)dialkyl-amino,
(C.sub.1-C.sub.6)dialkylamino(C.sub.1-C.sub.6)alkyl groups.
[0025] Among the compounds of formula (I) that are subjects of the
invention, mention may especially be made of the following
compounds: [0026] 1.
N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide- ;
[0027] 2.
7-chloro-N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide;
[0028] 3.
7-fluoro-N,N-9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-ca-
rboxamide; [0029] 4.
6-chloro-N,N-9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide;
[0030] 5.
7-chloro-N,N-dimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carbo-
xamide; [0031] 6.
7-chloro-N,N-diethyl-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxa-
mide; [0032] 7.
7-chloro-9-methyl-2-phenyl-4-(pyrrolidin-1-ylcarbonyl)-9H-pyrimido[4,5-b]-
indole; [0033] 8.
7-chloro-9-methyl-2-phenyl-4-(piperidin-1-ylcarbonyl)-9H-pyrimido[4,5-b]i-
ndole; [0034] 9.
7-chloro-9-methyl-4-(morpholin-4-ylcarbonyl)-2-phenyl-9H-pyrimido[4,5-b]i-
ndole; [0035] 10.
4-[(4-azetidin-1-yl)piperidin-1-ylcarbonyl]-7-chloro-9-methyl-2-phenyl-9H-
-pyrimido-[4,5-b]indole; [0036] 11.
7-chloro-9-methyl-4-[(4-methylpiperazin-1-yl)carbonyl]-2-phenyl-9H-pyrimi-
do[4,5-b]indole; [0037] 12.
6-chloro-N,N-9-trimethyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indole-4-carbox-
amide; [0038] 13.
7-fluoro-N,N,9-trimethyl-2-pyridin-4-yl-9H-pyrimidol]-4,5-b]indole-4-carb-
oxamide; [0039] 14.
7-chloro-9-methyl-2-pyridin-4-yl-4-(pyrrolidin-1-ylcarbonyl)-9H-pyrimido--
[4,5-b]indole; [0040] 15.
7-chloro-N,N,9-trimethyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indole-4-carbox-
amide; [0041] 16.
7-chloro-N,N,9-trimethyl-2-pyridin-3-yl-9H-pyrimido[4,5-b]indole-4-carbox-
amide; [0042] 17.
7-chloro-N,N-9-trimethyl-2-pyridin-2-yl-9H-pyrimido[4,5-b]indole-4-carbox-
amide [0043] 18.
7-chloro-N,N-9-trimethyl-2-pyrazin-2-yl-9H-pyrimido[4,5-b]indole-4-carbox-
amide; [0044] 19.
2-(7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indol-4-yl)-N,N-dimethyla-
cetamide; [0045] 20.
2-(6-chloro-9-methyl-2-phenyl-9H-pyrimido]4,5-b]indol-4-yl)-N,N-dimethyla-
cetamide; [0046] 21.
2-(7-chloro-9-methyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indol-4-yl)-N,N-dim-
ethylacetamide; [0047] 22.
2-(7-chloro-9-methyl-2-pyridin-3-yl-9H-pyrimido[4,5-b]indol-4-yl)-N,N-dim-
ethylacetamide; [0048] 23.
N,N-dimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide;
[0049] 24. ethyl
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate;
[0050] 25. methyl
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate;
[0051] 26.
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylic
acid; [0052] 27.
7-chloro-N,N-9-trimethyl-2-(6-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indol-
e-4-carboxamide; [0053] 28.
7-chloro-2-(6-methoxypyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indo-
le-4-carboxamide; [0054] 29.
7-chloro-N,N-9-trimethyl-2-(2-methylpyridin-4-yl)-9H-pyrimido[4,5-b]indol-
e-4-carboxamide; [0055] 30.
7-chloro-2-(2-methoxypyridin-4-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indo-
le-4-carboxamide; [0056] 31.
7-chloro-9-isobutyl-N,N-dimethyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indole--
4-carboxamide; [0057] 32.
7-chloro-2-cyclopropyl-N,N,9-trimethyl-9H-pyrimido[4,5-b]indole-4-carboxa-
mide; [0058] 33.
7-chloro-N,N,2,9-tetramethyl-9H-pyrimido[4,5-b]indole-4-carboxamide;
[0059] 34.
7-chloro-2-isopropyl-N,N,9-trimethyl-9H-pyrimido[4,5-b]indole-4-carboxami-
de; [0060] 35.
7-chloro-N,N,9-trimethyl-2-(tetrahydro-2H-pyran-4-yl)-9H-pyrimido[4,5-b]i-
ndole-4-carboxamide; [0061] 36.
7-chloro-2-{4-[(dimethylamino)methyl]phenyl-N,N,9-trimethyl-9H-pyrimido[4-
,5-b]indole-4-carboxamide; [0062] 37.
7-chloro-2-(6-chloropyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indol-
e-4-carboxamide; [0063] 38.
7-chloro-N,N,9-trimethyl-2-[6-trifluoromethyl)pyridin-3-yl]-9H-pyrimido[4-
,5-b]indole-4-carboxamide; [0064] 39.
7-chloro-2-(6-ethoxypyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indol-
e-4-carboxamide; [0065] 40.
7-chloro-2-(6-ethylpyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indole-
-4-carboxamide; [0066] 41.
7-chloro-2-(5-ethylpyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indole-
-4-carboxamide; [0067] 42.
7-chloro-N,N,9-trimethyl-2-(5-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indol-
e-4-carboxamide; [0068] 43.
7-chloro-N,N,9-trimethyl-2-pyrimidin-5-yl-9H-pyrimido[4,5-b]indole-4-carb-
oxamide; [0069] 44.
7-chloro-2-(5-methoxypyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indo-
le-4-carboxamide; [0070] 45.
7-chloro-2-[6-(methoxymethyl)pyridin-3-yl]-N,N,9-trimethyl-9H-pyrimido[4,-
5-b]indole-4-carboxamide; [0071] 46.
7-chloro-N,N,9-trimethyl-2-(2-methyl-1,3-thiazol-4-yl)-9H-pyrimido[4,5-b]-
indole-4-carboxamide; [0072] 47.
7-chloro-2-{6-[(dimethylamino)methyl]pyridin-3-yl}-N,N,9-trimethyl-9H-pyr-
imido[4,5-b]indole-4-carboxamide; [0073] 48.
7-chloro-2-(5,6-dimethylpyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]i-
ndole-4-carboxamide; [0074] 49.
7-chloro-N,N,9-trimethyl-2-(5,6,7,8-tetrahydroquinolin-3-yl)9H-pyrimido[4-
,5-b]indole-4-carboxamide; [0075] 50.
7-chloro-2-(2,6-dimethylpyridin-4-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]i-
ndole-4-carboxamide.
[0076] The compounds of general formula (I) may be prepared by the
processes illustrated by the following schemes.
[0077] The expression "leaving group" is understood to mean, in
that which follows, a group which may be easily split from a
molecule by cleavage of a heterolytic bond with departure of an
electron pair. This group can thus be easily replaced by another
group during a substitution reaction, for example. Such leaving
groups are, for example, halogens or an activated hydroxy group
such as a mesyl, tosyl, triflate, acetyl, etc. Examples of leaving
groups and also references for their preparation are given in
"Advances in Organic Chemistry", J. March, 3rd edition, Wiley
Interscience, p. 310-316.
##STR00003##
Synthetic Pathway for Carboxamides (n=0, Y.dbd.NR.sub.4R.sub.5)
[0078] As illustrated in scheme 1, a 2-oxindole of general formula
(II), in which X and R.sub.1 are as defined above, is converted to
2-chloroindole of general formula (III), in which X, R.sub.1,
R.sub.4 and R.sub.5 are as defined above, first by action of oxalyl
chloride in a polar aprotic solvent such as dichloromethane for
example, then by action of an amine of general formula
HNR.sub.4R.sub.5, in which R.sub.4 and R.sub.5 are as defined
above. The 2-chloroindole of general formula (III) is cyclized in
the presence of an alkyl, heteroalkyl, aryl or heteroaryl amidine
of general formula R.sub.2C(NH)NH.sub.2 in which R.sub.2 is as
defined above, by heating in an apolar or polar solvent such as for
example xylene or N,N-dimethylformamide in order to result in a
compound of general formula (I) in which X, R.sub.1, R.sub.2,
R.sub.4 and R.sub.5 are as defined above.
[0079] The compounds (Ib) for which
R.sub.1.dbd.(C.sub.1-C.sub.6)alkyl may be obtained from compounds
(Ia) for which R.sub.1.dbd.H via an alkylation reaction, for
example using 1,1-di(C.sub.1-C.sub.6)alkoxytrimethylamine in a
solvent such as hot toluene.
[0080] The compounds (IIb) for which
R.sub.1.dbd.(C.sub.1-C.sub.6)alkyl may be obtained from compounds
(IIa) for which R.sub.1.dbd.H via alkylation, for example using a
dialkylsulfate, by analogy to a procedure described in the
literature (G. W. Rewcastle et al., J. Med. Chem. (1994), 37,
2033).
[0081] The 2-oxindoles of general formula (IIa) are known in the
literature or are commercially available.
Synthetic Pathway for Carboxylic Esters (n=0; Y.dbd.OR.sub.3)
[0082] As illustrated in scheme 2, the 2-chloroindole of general
formula (IV), where X and R.sub.1 are as defined above, is
converted to pyrimido[4,5-b]indol-4-one (V) by treatment with
thionyl chloride, then by addition of an alkyl, heteroalkyl, aryl
or heteroaryl amidine of general formula R.sub.2C(NH)NH.sub.2 in
which R.sub.2 is as defined above and finally by heating in a
high-boiling-point solvent such as diphenyl ether for example. The
pyrimido[4,5-b]indol-4-one (V) may also be obtained from
2-aminoindole of general formula (VI) where X and R.sub.1 are as
defined above and R is a (C.sub.1-C.sub.6)alkyl, by making it react
with a cyanoaryl or cyanoheteroaryl derivative of general formula
R.sub.2CN in which R.sub.2 is as defined above, in the presence of
a base such as sodium hydride in a polar aprotic solvent such as
tetrahydrofuran, when hot.
[0083] The pyrimido[4,5-b]indol-4-one of general formula (V), in
which X, R.sub.1 and R.sub.2 are as defined above, is then
converted to a triflate of general formula (VII), in which X,
R.sub.1 and R.sub.2 are as defined above and OTf is a triflate
group, for example in the presence of trifluoromethanesulfonic
anhydride in a solvent such as dichloromethane. The ester of
general formula (I), in which X, R.sub.1, R.sub.2 and R.sub.3 are
as defined above, is finally obtained by a carbonylation reaction
of the triflate of general formula (VII), for example in the
presence of a catalyst such as palladium acetate, carbon monoxide,
a ligand of phosphine type such as
1,3-bis(diphenylphosphino)propane and an alcohol of general formula
R.sub.3OH, in which R.sub.3 is as defined above.
##STR00004##
[0084] The ester of general formula (I), in which n=0;
Y.dbd.OR.sub.3, R.sub.1.dbd.(C.sub.1-C.sub.6)alkyl, X, R.sub.2 and
R.sub.3 being as defined above, may also be obtained from the
corresponding amide of general formula (I) in which n=0,
Y.dbd.NR.sub.4R.sub.5, R.sub.1.dbd.(C.sub.1-C.sub.6)alkyl, X,
R.sub.2, R.sub.4 and R.sub.5 being as defined above, for example
when R.sub.4 and R.sub.5 represent, independently of one another, a
methyl via action at high temperature of an acid such as sulfuric
acid in an alcohol of general formula R.sub.3OH, in which R.sub.3
is as defined above.
[0085] The amides of general formula (I) in which n=0,
Y.dbd.NR.sub.4R.sub.5, X, R.sub.1, R.sub.2, R.sub.4 and R.sub.5
being as defined above, may also be obtained from an ester of
general formula (I) in which n=0, Y.dbd.OR.sub.3,
R.sub.3.dbd.(C.sub.1-C.sub.6)alkyl, X, R.sub.1 and R.sub.2 being as
defined above, via action of an amine of general formula
HNR.sub.4R.sub.5, in which R.sub.4 and R.sub.5 are as defined
above, for example in the presence of a trialkylaluminum derivative
in a solvent such as toluene.
[0086] The acids of general formula (I) in which n=0,
Y.dbd.OR.sub.3, R.sub.3.dbd.H, X, R.sub.1, R.sub.2 being as defined
above, may be obtained by saponification of the corresponding
esters for which R.sub.3.dbd.(C.sub.1-C.sub.6)alkyl, for example in
the presence of a base such as lithium hydroxide monohydrate in a
solvent such as a mixture of tetrahydrofuran, methanol and
water.
[0087] The amides of general formula (I) in which n=0,
Y.dbd.NR.sub.4R.sub.5, X, R.sub.1, R.sub.2, R.sub.4 and R.sub.5
being as defined above, may also be obtained by coupling the
corresponding acids of general formula (I) in which n=0,
Y.dbd.OR.sub.3 and R.sub.3.dbd.H with an amine of general formula
HNR.sub.4R.sub.5 as defined above, according to methods known to a
person skilled in the art.
Synthetic Pathway for Acetamides (n=1, Y.dbd.NR.sub.4R.sub.5)
[0088] According to scheme 3, a pyrimido[4,5-b]indol-4-one
derivative of general formula (V) as defined above, is converted to
a 4-halopyrimido[4,5-b]indole of general formula (VIII) where X,
R.sub.1 and R.sub.2 are as defined above and Hal is a halogen atom,
by using a halogenating agent, for example oxalyl chloride in a
polar aprotic solvent such as N,N-dimethylformamide, at high
temperature. The compound of general formula (VIII) may then be
condensed with a malonate of general formula
R'O(CO)CH.sub.2(CO)NR.sub.4R.sub.5, in which R.sub.4 and R.sub.5
are as defined above and R' is a (C.sub.1-C.sub.6)alkyl, in the
presence of a base and a metal salt such as a copper salt resulting
in a compound of general formula (IX) in which X, R.sub.1, R.sub.2,
R.sub.4, R.sub.5 and R' are as defined above.
[0089] Finally, the derivative of general structure (IX) may be
saponified and decarboxylated by using, for example, lithium
hydroxide, in a mixture of methanol, water and an ethereal solvent,
to result in the amide of general formula (I) in which X, R.sub.1,
R.sub.2, R.sub.4 and R.sub.5 are as defined above.
##STR00005##
Synthetic Pathway for Acetic Esters (n=1, Y.dbd.OR.sub.3)
[0090] The esters of general formula (I), in which n=1,
Y.dbd.OR.sub.3, R.sub.1.dbd.(C.sub.1-C.sub.6)alkyl, R.sub.2 and
R.sub.3 being as defined above, may be obtained from the
corresponding amide of general formula (I) in which n=1,
Y.dbd.NR.sub.4R.sub.5, R.sub.1.dbd.(C.sub.1-C.sub.6)alkyl, R.sub.2,
R.sub.4 and R.sub.5 being as defined above, for example when
R.sub.4 and R.sub.5 represent, independently of one another, a
methyl, via action of an acid such as sulfuric acid in a hot
alcohol-based solvent.
[0091] The acids of general formula (I) in which n=1,
Y.dbd.OR.sub.3, R.sub.3.dbd.H, R.sub.1, R.sub.2 being as defined
above, may be obtained from the corresponding esters for which
R.sub.3.dbd.(C.sub.1-C.sub.6)alkyl, for example in the presence of
a base such as lithium hydroxide monohydrate in a solvent such as a
mixture of tetrahydrofuran, methanol and water.
[0092] The starting compounds of general formula (IIa), (IIb), (IV)
and (VI), when their method of preparation is not described, are
commercially available or are described in the literature, or else
may be prepared according to the methods which are described
therein or which are known to a person skilled in the art.
[0093] The 2-chloroindoles of general formula (IV), for which
X.dbd.H, are described in the literature (by way of example,
mention may be made of: H. D. H. Showalter et al., J. Med. Chem.
(1997), 40, 413; P. Kutschy et al., Tetrahedron (2002), 58, 9029).
The 2-chloroindoles of general formula (IV) for which X is other
than H may be obtained from the 2-oxindoles of general formula
(IIb) by analogy to methods described in the literature (by way of
example, mention may be made of: L. Sun et al., J. Heterocyclic
Chem. (1997), 34, 1399) under Vilsmeier type reaction conditions,
then via oxidation of the aldehyde obtained.
[0094] The 2-aminoindoles of general formula (VI), for which
R.sub.1.dbd.H, are described or prepared by methods known in the
literature (by way of example, mention may be made of: A. Suga et
al., JP 2002 155083, A. Suga et al., WO 0174817; K. L. Munshi et
al., J. Heterocyclic Chem. (1977), 14, 1145; C. A. Grob et al.,
Helv. Chim. Acta, (1961), 44, 1748; I. T. Forbes et al., J. Chem.
Soc. Perkin Trans. 1, (1992), 275). The aminoindoles of general
formula (VI), for which R.sub.1 is other than H, are described in
the case where X.dbd.H and R.sub.1=Me (R. A. Glennon et al., J.
Heterocyclic Chem. (1975), 12, 135). The aminoindoles of general
formula (VI), for which R.sub.1 is other than H, may be obtained by
an alkylation reaction from 2-aminoindoles of general formula (VI)
for which R.sub.1.dbd.H by analogy to methods described in the
literature (by way of example, mention may be made of: I. T. Forbes
et al., J. Chem. Soc. Perkin Trans. 1, (1992), 275; R. A. Glennon
et al., J. Heterocyclic Chem. (1975), 12, 135).
[0095] The carboxamidines are known in the literature or else may
be prepared according to methods which are described therein or
which are known to a person skilled in the art, for example the
production of carboxamidine from nitrile. By way of example,
mention may be made of the pyrazine-2-carboxamidine described in:
J. K. Chakrabarti et al., EP 455 356.
[0096] The malonates of general formula
R'O(CO)CH.sub.2(CO)NR.sub.4R.sub.5 are known in the literature and
may be prepared according to the methods which are described
therein. Mention will be made, by way of example, of: W. Sucrow et
al., Chem. Berichte (1968), 101(12), 4230.
[0097] The amines of general formula HNR.sub.4R.sub.5 are
commercially available or are described in the literature. By way
of example, the amines for which R.sub.4 and R.sub.5 form a
piperidinyl ring substituted by an azetidinyl group may be prepared
by analogy to a method described in the literature (P. C. Ting et
al., Bioorg. Med. Chem. Lett. (2001), 11, 491).
[0098] According to another of these aspects, another subject of
the invention is the compounds of formulae (III), (VII) and (IX).
These compounds are useful as intermediates for synthesizing
compounds of formula (I).
[0099] The examples which follow illustrate the preparation of some
compounds of the invention. These examples are not limiting and
only illustrate the present invention. The numbers of the compounds
exemplified reflect those given in the table below, which
illustrates the chemical structures and the physical properties of
some compounds according to the invention. The elementary
microanalyses and the IR and NMR spectra confirm the structures of
the compounds obtained.
EXAMPLE 1
Compound No. 16
7-chloro-N,N,9-trimethyl-2-pyridin-3-yl-9H-pyrimido[4,5-b]indole-4-carboxa-
mide
1.1. 6-chloro-1-methyl-1,3-dihydro-2H-indol-2-one
[0100] 20 g (0.119 mol) of 6-chloro-1,3-dihydro-2H-indol-2-one were
introduced into 600 ml of water. Next, 17 ml (0.180 mol) of
dimethyl sulfate and 7.2 g (0.180 mol) of sodium hydroxide pellets
were added. The mixture was heated at 100.degree. C. for 20 min.
The hot mixture was filtered. The insoluble part containing the
starting oxindole was kept. The filtrate was cooled with an ice
bath, then it was filtered. A white solid was recovered that was
rinsed with water. The insoluble part obtained in the first
filtration was added to the filtrate, then 17 ml (0.180 mol) of
dimethyl sulfate and 7.2 g (0.180 mol) of sodium hydroxide pellets
were added. The mixture was brought to 100.degree. C. for 20 min.
The hot mixture was filtered. The insoluble part was kept. The
filtrate was cooled with an ice bath, then it was filtered. A white
solid was recovered that was rinsed with water. This cycle was then
repeated 3 times. At the end, the solids obtained from the various
filtrations were combined and they were dried under vacuum in the
presence of phosphorus pentoxide. The solid was purified by
chromatography on a column of neutral alumina gel with a mixture of
solvents (petroleum ether/dichloromethane:20/80).
[0101] 9.8 g of 6-chloro-1-methyl-1,3-dihydro-2H-indol-2-one were
isolated in the form of a white solid.
[0102] M.P.: 116-117.degree. C.
1.2.
2-(2,6-dichloro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide
[0103] 5.4 ml (63 mmol) of oxalyl chloride were introduced under
nitrogen into 100 ml of dichloromethane. Next, a solution of 5.0 g
(27.5 mmol) of 6-chloro-1-methyl-1,3-dihydro-2H-indol-2-one,
obtained in step 1.1, in 30 ml of dichloromethane was slowly added.
The mixture was heated under reflux for 4 h. The mixture was
cooled, then concentrated under reduced pressure. Under nitrogen,
the residue was dissolved in 200 ml of dichloromethane, then the
mixture was cooled to 0.degree. C. The reaction medium was
saturated with gaseous dimethylamine until a basic pH was obtained.
After stirring for 15 min, the mixture was concentrated under
reduced pressure. The residue was purified by chromatography on a
silica gel column with a mixture of solvents
(dichloromethane/methanol: 100/0 to 99/1).
[0104] 5.0 g of compound was isolated in the form of a white
solid.
[0105] M.P.: 146-148.degree. C.
1.3.
7-chloro-N,N,9-trimethyl-2-pyridin-3-yl-9H-pyrimido[4,5-b]indole-4-ca-
rboxamide
[0106] 0.3 g (13 mmol) of sodium was dissolved under nitrogen in
100 ml of absolute ethanol. Next, 1.0 g (6.34 mmol) of
pyridine-3-carboxamidine hydrochloride was added. After stirring
for 2 h, the mixture was concentrated under reduced pressure.
Dichloromethane was added and it was filtered. The filtrate was
concentrated under reduced pressure. Added to the residue were 100
ml of xylene, then 0.34 g (1.13 mmol) of
2-(2,6-dichloro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide
obtained in step 1.2. The mixture was heated under reflux for 18 h.
Then it was cooled and concentrated under reduced pressure.
Dichloromethane, water and a (1M) aqueous solution of sodium
hydroxide was added.
[0107] The organic phase was decanted then washed with water, dried
over sodium sulfate, filtered and concentrated under reduced
pressure. The residue was purified by chromatography on a silica
gel column with a mixture of solvents (dichloromethane/ethyl
acetate: 80/20 to 0/100). The compound obtained was recrystallized
in a dichloromethane/ethyl acetate mixture, it was isolated by
filtration, rinsed with diethyl ether and dried under reduced
pressure.
[0108] 0.18 g of
7-chloro-N,N,9-trimethyl-2-pyridin-3-yl-9H-pyrimido[4,5-b]indole-4-carbox-
amide was isolated in the form of a white solid.
[0109] M.P.: 283-284.degree. C.
[0110] LC/MS: M.sup.+H=366.
[0111] .sup.1H NMR (CDCl.sub.3, 200 MHz): 9.8 (s, 1H); 8.9 (m, 1H);
8.7 (m, 1H); 8.1 (d, 1H); 7.3-7.5 (m, 3H); 4.0 (s, 3H); 3.5 (s,
3H); 3.1 (s, 3H).
EXAMPLE 2
Compound No. 15
7-chloro-N,N,9-trimethyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indole-4-carboxa-
mide
2.1. pyridine-4-carboxamidine
[0112] 0.44 g (19 mmol) of sodium was dissolved under nitrogen in
100 ml of methanol. Next, 3.0 g (19 mmol) of
pyridine-4-carboxamidine hydrochloride dissolved in 50 ml of
methanol was added. After stirring for 30 minutes, the mixture was
concentrated under reduced pressure. 150 ml of chloroform were
added to the residue and the mixture was heated under reflux. It
was then filtered over celite.TM.. The filtrate was cooled and
concentrated under reduced pressure.
[0113] 2.25 g of pyridine-4-carboxamidine was obtained in the form
of a white solid.
[0114] M.P.: 136-140.degree. C.
2.2.
7-chloro-N,N,9-trimethyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indole-4-ca-
rboxamide
[0115] A solution of 2.75 g (9.4 mmol) of
2-(2,6-dichloro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,
obtained according to step 1.2. from example 1, and 4.2 g (34.6
mmol) of pyridine-4-carboxamidine obtained according to step 2.1.
in 40 ml of N,N-dimethylformamide and 10 ml of 1,4-dioxane were
heated at 130.degree. C. for 6 h. After returning to ambient
temperature a compound precipitated. It was isolated by filtration
and rinsed with ethyl acetate. The solid was recrystallized in an
ethyl acetate/methanol mixture. It was then purified by
chromatography on a silica gel column with a mixture of solvents
(dichloromethane/methanol:98/2). A white solid was recovered that
was recrystallized in an ethyl acetate/methanol mixture, then
isolated by filtration, rinsed with diethyl ether and dried under
reduced pressure.
[0116] 1.1 g of
7-chloro-N,N,9-trimethyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indole-4-carbox-
amide was isolated in the form of a white solid.
[0117] M.P.: 268-269.degree. C.
[0118] LC/MS: M.sup.+H=366
[0119] .sup.1H NMR (CDCl.sub.3, 200 MHz): 8.8 (d, 2H); 8.5 (d, 2H);
8.1 (d, 1H); 7.5 (d, 1H); 7.3 (dd, 1H); 4.0 (s, 3H); 3.5 (s, 3H);
3.1 (s, 3H).
EXAMPLE 3
Compound No. 18
7-chloro-N,N,9-trimethyl-2-pyrazin-2-yl-9H-pyrimido[4,5-b]indole-4-carboxa-
mide
[0120] 0.6 g (26 mmol) of sodium was dissolved under nitrogen in
150 ml of absolute ethanol. Next, 1.2 g (7.6 mmol) of
pyrazine-2-carboxamidine hydrochloride was added.
[0121] After stirring for 1 h 30 min, the residual insoluble part
was isolated by filtration and the filtrate was concentrated under
reduced pressure. 150 ml of dichloromethane was added and the
mixture was filtered. The filtrate was concentrated under reduced
pressure. Added to the residue were 100 ml of xylene, then 0.24 g
(0.80 mmol) of
2-(2,6-dichloro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,
obtained according to step 1.2. from example 1. The mixture was
heated under reflux for 18 h. It was then cooled and concentrated
under reduced pressure. Dichloromethane, water and a (1M) aqueous
solution of sodium hydroxide was added. The organic phase was
decanted, washed with water, dried over sodium sulfate, filtered
and concentrated under reduced pressure. The residue was purified
by chromatography on a silica gel column with a mixture of solvents
(dichloromethane/ethyl acetate: 80/20 to 0/100, then ethyl
acetate/methanol: 100/0 to 95/5). The compound obtained was
recrystallized in an ethyl acetate/methanol mixture, it was
isolated by filtration, rinsed with diethyl ether and dried under
reduced pressure.
[0122] 0.070 g of
7-chloro-N,N,9-trimethyl-2-pyrazin-2-yl-9H-pyrimido[4,5-b]indole-4-carbox-
amide was isolated in the form of a white solid.
[0123] M.P.: 272-273.degree. C.
[0124] LC/MS: M.sup.+H=367
[0125] .sup.1H NMR (CDCl.sub.3, 200 MHz): 9.9 (s, 1H); 8.9 (d, 1H);
8.7 (d, 1H); 8.1 (d, 1H); 7.6 (d, 1H); 7.4 (dd, 1H); 4.1 (s, 3H);
3.4 (s, 3H); 3.1 (s, 3H).
EXAMPLE 4
Compound No. 14
7-chloro-9-methyl-2-pyridin-4-yl-4-(pyrrolidin-1-ylcarbonyl)-9H-pyrimido[4-
,5-b]indole
4.1.
1-(2,6-dichloro-1-methyl-1H-indol-3-yl)-2-oxo-2-pyrrolidin-1-ylethano-
ne
[0126] 5.0 ml (58.2 mmol) of oxalyl chloride was introduced under
nitrogen into 120 ml of dichloromethane. Next, a solution of 3.0 g
(16.5 mmol) of 6-chloro-1-methyl-1,3-dihydro-2H-indol-2-one,
obtained in step 1.1 from example 1, in 30 ml of dichloromethane
was slowly added. The mixture was heated under reflux for 4 h. The
mixture was cooled, then concentrated under reduced pressure. Under
nitrogen, the residue was dissolved in 150 ml of dichloromethane
and the mixture was cooled to 0.degree. C. Next, 2.8 ml (33.8 mmol)
of pyrrolidine were slowly added. After stirring for around 15 min,
a 1M aqueous solution of hydrochloric acid was added up to a pH of
3-4. The organic phase was decanted, washed with water, dried over
sodium sulfate, filtered and concentrated under reduced pressure.
The residue was purified by chromatography on a silica gel column
with a mixture of solvents (dichloromethane/ethyl acetate: 95/5 to
70/30). The solid obtained was recrystallized in a
dichloromethane/ethyl acetate mixture, isolated by filtration,
rinsed with diethyl ether and dried under reduced pressure.
[0127] 3.3 g of
1-(2,6-dichloro-1-methyl-1H-indol-3-yl)-2-oxo-2-pyrrolidin-1-ylethanone
was isolated in the form of a white solid.
[0128] M.P.: 174-175.degree. C.
4.2.
7-chloro-9-methyl-2-pyridin-4-yl-4-(pyrrolidin-1-ylcarbonyl)-9H-pyrim-
ido[4,5-b]indole
[0129] A solution of 1.0 g (3.07 mmol) of
1-(2,6-dichloro-1-methyl-1H-indol-3-yl)-2-oxo-2-pyrrolidin-1-ylethanone,
obtained in step 4.1, and 1.3 g (10.6 mmol) of
pyridine-4-carboxamidine, obtained in step 2.1 from example 2, in
60 ml of xylene were heated under reflux for 5 h. After returning
to ambient temperature, the mixture was concentrated under reduced
pressure. 200 ml of dichloromethane was added, the organic phase
was washed with a saturated sodium hydrogencarbonate aqueous
solution, then with water. The organic phase was dried over sodium
sulfate, filtered and concentrated under reduced pressure. The
residue was purified by chromatography on a silica gel column with
a mixture of solvents (dichloromethane/ethyl acetate: 90/10 to
0/100). A white solid was recovered that was recrystallized in a
dichloromethane/ethyl acetate mixture, then isolated by filtration,
rinsed with diethyl ether and dried under reduced pressure.
[0130] 0.40 g of
7-chloro-9-methyl-2-pyridin-4-yl-4-(pyrrolidin-1-ylcarbonyl)-9H-pyrimido[-
4,5-b]indole was isolated in the form of a white solid.
[0131] M.P.: 256-258.degree. C.
[0132] LC/MS: M.sup.+H=392.
[0133] .sup.1H NMR (CDCl.sub.3, 300 MHz): 8.8 (m, 2H); 8.5 (m, 2H);
8.4 (d, 1H); 7.5 (d, 1H); 7.4 (d, 1H); 4.0 (s, 3H); 3.9 (t, 2H);
3.8 (t, 2H); 2.1-1.9 (m, 4H).
EXAMPLE 5
Compound No. 5
7-chloro-N,N-dimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide
5.1. 2-(2,6-dichloro-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide
[0134] Under nitrogen, 8 ml (91.7 mmol) of oxalyl chloride were
introduced into 150 ml of dichloromethane. Next, 5.0 g (29.8 mmol)
of 6-chloro-1,3-dihydro-2H-indol-2-one were added in small
portions. The mixture was stirred for 2 h at ambient temperature,
then 4 h under reflux. The mixture was cooled, then concentrated
under reduced pressure. Under nitrogen, the residue was dissolved
in 150 ml of dichloromethane and the mixture was cooled to
0.degree. C. The reaction medium was saturated with gaseous
dimethylamine until a basic pH was obtained. After stirring for 15
min, a 1M aqueous solution of hydrochloric acid was added until a
pH of 2-3. Next, 300 ml of dichloromethane and 100 ml of water were
added. The organic phase was decanted, washed with water, dried
over sodium sulfate, filtered and concentrated under reduced
pressure. The residue was purified by chromatography on a silica
gel column with a mixture of solvents (dichloromethane/ethyl
acetate: 90/10 to 50/50). The solid obtained was rinsed with
diethyl ether and dried under reduced pressure.
[0135] 3.2 g of
2-(2,6-dichloro-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide was
isolated in the form of a white solid.
[0136] M.P.: 223-224.degree. C.
5.2.
7-chloro-N,N-dimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide
[0137] Under nitrogen, 0.2 g (8.3 mmol) of sodium were dissolved in
100 ml of absolute ethanol. Next, 1.0 g (6.38 mmol) of benzamidine
hydrochloride were added. After stirring for 30 minutes, the
mixture was concentrated under reduced pressure. Dichloromethane
was added and the mixture was filtered. The filtrate was
concentrated under reduced pressure. Added to the residue were 120
ml of toluene, then 0.30 g (1.2 mmol) of
2-(2,6-dichloro-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,
obtained in step 5.1. from example 5. The mixture was heated under
reflux for 18 h. Then it was cooled and concentrated under reduced
pressure. Dichloromethane and water were added. The organic phase
was decanted, washed with water, dried over sodium sulfate,
filtered and concentrated under reduced pressure. The residue was
purified by chromatography on a silica gel column with a mixture of
solvents (dichloromethane/ethyl acetate: 95/5 to 50/50). The
compound obtained was recrystallized in a dichloromethane/ethyl
acetate mixture, isolated by filtration, rinsed with diethyl ether
and dried under reduced pressure.
[0138] 0.09 g of
7-chloro-N,N-dimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide
were isolated in the form of a white solid.
[0139] M.P.: 232-233.degree. C.
[0140] LC/MS: M.sup.+H=351
[0141] .sup.1H NMR (DMSO-d.sub.6, 200 MHz): 12.7 (s, 1H); 8.5 (m,
2H); 7.9 (d, 1H); 7.5-7.6 (m, 4H); 7.4 (dd, 1H); 3.2 (s, 3H); 3.0
(s, 3H).
EXAMPLE 6
Compound No. 4
6-chloro-N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide
6.1. 5-chloro-1-methyl-1,3-dihydro-2H-indol-2-one
[0142] 13.3 g (0.795 mol) of 5-chloro-1,3-dihydro-2H-indol-2-one
were introduced into 200 ml of water. Next, 120 ml of a 1M solution
of sodium hydroxide and 11.3 ml (0.120 mol) of dimethyl sulfate
were added. The mixture was heated to 120.degree. C. for 30 min. It
was left to cool, then 4.81 g (120 mmol) of sodium hydroxide and
11.3 ml (0.120 mol) of dimethyl sulfate were added. The mixture was
heated to 120.degree. C. for 30 min. It was left to cool and the
operation was repeated once more. Next, the reaction mixture was
filtered and the precipitate was rinsed with water and dried under
vacuum in the presence of phosphorus pentoxide. 250 ml of
dichloromethane were added to the filtrate. The organic phase was
decanted, washed with water, dried over sodium sulfate, filtered
and concentrated under reduced pressure. The precipitate was added
to the residue obtained and the assembly was purified by
chromatography on a neutral alumina gel column with a mixture of
solvents (dichloromethane/ethyl acetate: 98/2 to 50/50).
[0143] 3.9 g of 5-chloro-1-methyl-1,3-dihydro-2H-indol-2-one were
isolated in the form of a white solid.
[0144] M.P.: 118-119.degree. C.
6.2.
2-(2,5-dichloro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide
[0145] Under nitrogen, 8.1 ml (92.8 mmol) of oxalyl chloride were
introduced into 150 ml of dichloromethane. Next, 3.9 g (30.7 mmol)
of 5-chloro-1-methyl-1,3-dihydro-2H-indol-2-one, obtained in step
6.1. from example 6, were added in small portions. The mixture was
heated under reflux for 4 h. The mixture was cooled, then
concentrated under reduced pressure. The residue was dissolved
under nitrogen in 120 ml of dichloromethane and the mixture was
cooled to 0.degree. C. The reaction medium was saturated with
gaseous dimethylamine until a basic pH was obtained. After stirring
for 15 min, the mixture was concentrated under reduced pressure.
The following were added: 250 ml of dichloromethane, 100 ml of
water and a 1M aqueous solution of hydrochloric acid up to a pH of
3-4. The organic phase was decanted, washed with water, dried over
sodium sulfate, filtered and concentrated under reduced pressure.
The residue was purified by chromatography on a silica gel column
with a mixture of solvents (dichloromethane/ethyl acetate: 95/5 to
50/50).
[0146] 1.45 g of
2-(2,5-dichloro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide
were isolated in the form of a white solid.
[0147] M.P.: 205-206.degree. C.
6.3.
6-chloro-N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxam-
ide
[0148] Under nitrogen, 0.34 g (14.8 mmol) of sodium were dissolved
in 120 ml of absolute ethanol. Next, 2.0 g (12.8 mmol) of
benzamidine hydrochloride were added. After stirring for 30
minutes, the mixture was concentrated under reduced pressure.
Dichloromethane was added and the mixture was filtered. The
filtrate was concentrated under reduced pressure. Added to the
residue were 60 ml of xylene, then 0.90 g (3 mmol) of
2-(2,5-dichloro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,
obtained in step 6.2. from example 6. The mixture was heated under
reflux for 3 h. Then it was cooled and concentrated under reduced
pressure. Dichloromethane and water were added. The organic phase
was decanted, washed with water, dried over sodium sulfate,
filtered and concentrated under reduced pressure. The residue was
purified by chromatography on a silica gel column with a mixture of
solvents (dichloromethane/ethyl acetate: 95/5 to 50/50). The
compound obtained was recrystallized in a dichloromethane/ethyl
acetate mixture, isolated by filtration, rinsed with diethyl ether
and dried under reduced pressure.
[0149] 0.53 g of
6-chloro-N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide
were isolated in the form of a white solid.
[0150] M.P.: 222-224.degree. C.
[0151] LC/MS: M.sup.+H=365.
[0152] .sup.1H NMR (CDCl.sub.3, 200 MHz): 8.7 (m, 2H); 8.1 (d, 1H);
7.6-7.5 (m, 4H); 7.4 (d, 1H); 4.1 (s, 3H); 3.4 (s, 3H); 3.2 (s,
3H).
EXAMPLE 7
Compound No. 23)
[0153]
N,N-dimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide
7.1. 2-(2-chloro-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide
[0154] Under nitrogen, 7.9 ml (90.5 mmol) of oxalyl chloride were
introduced into 150 ml of dichloromethane. Next, 6.0 g (45 mmol) of
1,3-dihydro-2H-indol-2-one were added in small portions. The
mixture was stirred at ambient temperature for 4 h. Next, the solid
was filtered and dissolved in 150 ml of dichloromethane. The
mixture was cooled to 0.degree. C. The reaction medium was
saturated with gaseous dimethylamine until a basic pH was obtained.
After stirring for 5 minutes, the mixture was concentrated under
reduced pressure. The residue was purified by chromatography on a
silica gel column with a mixture of solvents (dichloromethane/ethyl
acetate: 95/5 to 50/50).
[0155] 2.46 g of
2-(2-chloro-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide were
isolated in the form of a white solid.
[0156] M.P.: 197-198.degree. C.
7.2.
N,N-dimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide
[0157] Under nitrogen, 0.40 g (17.4 mmol) of sodium were dissolved
in 100 ml of methanol. Next, 2.72 g (17.4 mmol) of benzamidine
hydrochloride were added. After stirring for 30 minutes, the
mixture was concentrated under reduced pressure. Dichloromethane
was added and the mixture was filtered. The filtrate was
concentrated under reduced pressure. Added to the residue were 100
ml of xylene, then 1.52 g (6.1 mmol) of
2-(2-chloro-1H-indol-3-yl)-N,N-dimethyl-2-oxo-acetamide obtained in
step 7.1. from example 7. The mixture was heated under reflux for 5
h. Then it was cooled and concentrated under reduced pressure.
Dichloromethane and water were added. The organic phase was
decanted, washed with water, dried over sodium sulfate, filtered
and concentrated under reduced pressure. The residue was purified
by chromatography on a silica gel column with a mixture of solvents
(dichloromethane/ethyl acetate: 90/10 to 70/30). The fractions
containing the compound were concentrated, under reduced pressure,
until the appearance of a precipitate. It was isolated by
filtration, rinsed with diethyl ether and dried under reduced
pressure.
[0158] 1.36 g of
N,N-dimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide were
isolated in the form of a white solid.
[0159] M.P.: 218-219.degree. C.
[0160] MS: M.sup.+H=317.
[0161] .sup.1H NMR (DMSO-d.sub.6, 200 MHz): 12.6 (s, 1H); 8.5 (m,
2H); 7.9 (d, 1H); 7.6-7.5 (m, 5H); 7.3 (m, 1H); 3.2 (s, 3H); 2.9
(s, 3H).
EXAMPLE 8
Compound No. 1
N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide
[0162] Under nitrogen, 0.40 g (1.3 mmol) of
N,N-dimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide
obtained in step 7.2. from example 7 and 1 ml (7.5 mmol) of
1.1-dimethoxytrimethylamine in 120 ml of toluene were heated under
reflux for 6 h. Next, the mixture was cooled to room temperature
and concentrated under reduced pressure. The residue was purified
by chromatography on a silica gel column with a mixture of solvents
(dichloromethane/ethyl acetate: 100/0 to 50/50). The fractions
containing the product were combined and concentrated under reduced
pressure. The compound was recrystallized in ethyl acetate,
isolated by filtration, rinsed with diethyl ether and dried under
reduced pressure.
[0163] 0.33 g of
N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide
were isolated in the form of a white solid.
[0164] M.P.: 193-195.degree. C.
[0165] LC/MS: M.sup.+H=331.
[0166] .sup.1H NMR (CDCl.sub.3, 200 MHz): 8.7 (m, 2H); 8.1 (d, 1H);
7.6-7.5 (m, 5H); 7.4 (m, 1H); 4.1 (s, 3H); 3.4 (s, 3H); 3.1 (s,
3H).
EXAMPLE 9
Compound No. 3
7-fluoro-N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide
9.1. 6-fluoro-1-methyl-1,3-dihydro-2H-indol-2-one
[0167] 10.0 g (66.5 mmol) of 6-fluoro-1,3-dihydro-2H-indol-2-one
were introduced into 200 ml of water. Next, 120 ml of a 1M solution
of sodium hydroxide and 11.3 ml (120 mmol) of dimethyl sulfate were
added. The mixture was heated to 120.degree. C. for 40 min. After
returning to ambient temperature, 150 ml of dichloromethane and
water were added. The organic phase was decanted, washed with
water, dried over sodium sulfate, filtered and concentrated under
reduced pressure. The residue was purified by chromatography on a
neutral alumina gel column with a mixture of solvents
(dichloromethane/ethyl acetate: 98/2 to 80/20). The compound
obtained was rinsed with diethyl ether and dried under reduced
pressure.
[0168] 5.1 g of 6-fluoro-1-methyl-1,3-dihydro-2H-indol-2-one were
isolated in the form of a yellowish compound.
[0169] M.P.: 100-101.degree. C.
9.2.
2-(2-chloro-6-fluoro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetam-
ide
[0170] Under nitrogen, 5.0 ml (58.2 mmol) of oxalyl chloride were
introduced into 120 ml of dichloromethane. Next, a solution of 4.2
g (25.4 mmol) of 6-fluoro-1-methyl-1,3-dihydro-2H-indol-2-one,
obtained in step 9.1 from example 9, were slowly added in small
portions. The mixture was heated under reflux for 4 h. The mixture
was cooled, then concentrated under reduced pressure.
[0171] Under nitrogen, the residue was dissolved in 120 ml of
dichloromethane and the mixture was cooled to 0.degree. C. The
reaction medium was saturated with gaseous dimethylamine until a
basic pH was obtained. After stirring for 15 min, a 1M aqueous
solution of hydrochloric acid was added up to a pH of 3-4. Next,
100 ml of dichloromethane was added. The organic phase was
decanted, washed with water, dried over sodium sulfate, filtered
and concentrated under reduced pressure. The residue was purified
by chromatography on a silica gel column with a mixture of solvents
(dichloromethane/ethyl acetate: 95/5 to 50/50). The fractions
containing the compound were concentrated under reduced pressure
until the appearance of a precipitate. It was recovered by
filtration and rinsed with diethyl ether and dried under reduced
pressure.
[0172] 3.5 g of
2-(2-chloro-6-fluoro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide
were isolated in the form of a white compound.
[0173] M.P.: 175-177.degree. C.
9.3.
7-fluoro-N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxam-
ide
[0174] Under nitrogen, 0.28 g (12.17 mmol) of sodium were dissolved
in 120 ml of methanol. Next, 1.89 g (12.07 mmol) of benzamidine
hydrochloride were added. After stirring for 30 minutes, the
mixture was concentrated under reduced pressure. Dichloromethane
was added and the mixture was filtered. The filtrate was
concentrated under reduced pressure. Added to the residue were 50
ml of xylene, then 0.80 g (2.8 mmol) of
2-(2-chloro-6-fluoro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,
obtained in step 9.2. from example 9. The mixture was heated under
reflux for 6 h. Then it was cooled and concentrated under reduced
pressure. Dichloromethane and water were added. The organic phase
was decanted, washed with water, dried over sodium sulfate,
filtered and concentrated under reduced pressure. The residue was
purified by chromatography on a silica gel column with a mixture of
solvents (dichloromethane/ethyl acetate: 98/2 to 90/10). The
fractions containing the compound were concentrated under reduced
pressure until the appearance of a precipitate. It was recovered by
filtration and rinsed with diethyl ether. The compound obtained was
recrystallized in a dichloromethane/ethyl acetate mixture, isolated
by filtration, rinsed with diethyl ether and dried under reduced
pressure.
[0175] 0.40 g of
7-fluoro-N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide
was isolated in the form of a white solid.
[0176] M.P.: 229-231.degree. C.
[0177] LC/MS: M.sup.+H=349.
[0178] .sup.1H NMR (DMSO-d.sub.6, 200 MHz): 8.6 (m, 2H); 7.9 (dd,
1H) 7.7 (dd, 1H); 7.5 (m, 3H); 7.2 (m, 1H); 4.0 (s, 3H); 3.2 (s,
3H); 3.0 (s, 3H).
EXAMPLE 10
Compound No. 24
Ethyl
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate
[0179] A solution of 1.6 g (4.4 mmol) of
7-chloro-N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide,
obtained according to example 16 in 80 ml of absolute ethanol and
2.5 ml of sulfuric acid was heated under reflux for 48 h. The
mixture was cooled to ambient temperature and partially
concentrated under reduced pressure. Next, crushed ice and
dichloromethane were added. The organic phase was decanted, washed
with water, dried over sodium sulfate, filtered and concentrated
under reduced pressure. The residue was purified by chromatography
on a silica gel column with a mixture of solvents
(dichloromethane/ethyl acetate: 100/0 to 80/20). The fractions
containing the compound were concentrated under reduced pressure.
The residue was taken up by cyclohexane, recovered by filtration
and rinsed with pentane.
[0180] 0.46 g of ethyl
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate
were isolated in the form of a white compound.
[0181] M.P.: 139-140.degree. C.
[0182] MS: M+H=366.
[0183] .sup.1H NMR (CDCl.sub.3, 200 MHz): 8.8 (d, 1H); 8.6 (m, 2H);
7.6-7.5 (m, 4H); 7.3 (dd, 1H); 4.7 (q, 2H); 4.0 (s, 3H); 1.6 (t,
3H).
EXAMPLE 11
Compound No. 11
7-chloro-9-methyl-4-[(4-methylpiperazin-1-yl)carbonyl]-2-phenyl-9H-pyrimid-
o[4,5-b]indole
[0184] Added to 30 ml of toluene were 4 ml (8 mmol) of a solution
of trimethylaluminum (2M in toluene) under argon. The solution was
cooled to 0.degree. C., then 0.80 g (8 mmol) of 4-methylpiperazine
was added in portions. Stirring was continued for 1H at ambient
temperature. Next, 0.46 g (1.20 mmol) of ethyl
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate
obtained in example 10 was added. The reaction medium was heated
under reflux for 3 h. The solution was cooled to around 0.degree.
C., then water was added dropwise. Added next were dichloromethane,
then a concentrated solution of sodium hydroxide. The organic phase
was decanted, washed with water, dried over sodium sulfate, then
filtered and concentrated under reduced pressure. The residue was
purified by chromatography on a silica gel column with a mixture of
solvents (dichloromethane/ethyl acetate: 50/50, then pure ethyl
acetate, then ethyl acetate/methanol:95/5). The fractions
containing the compound were concentrated under reduced
pressure.
[0185] 0.54 g of a white compound was isolated. Added to this
compound were dichloromethane and 13 ml of a 0.1N solution of
hydrochloric acid in propane-2-ol. The solution was concentrated
under reduced pressure. The residue was recrystallized in ethanol
and rinsed with diethyl ether. Added to the compound obtained were
dichloromethane then a 1M aqueous solution of sodium hydroxide. The
organic phase was decanted, washed with water, dried over sodium
sulfate, filtered and concentrated under reduced pressure. The
residue was purified by chromatography on a silica gel column with
a mixture of solvents (dichloromethane/methanol:98/2 to 90/10). The
fractions containing the compound were concentrated under reduced
pressure. The compound obtained was recrystallized in a
dichloromethane/ethyl acetate mixture, it was recovered by
filtration, rinsed with diethyl ether and dried under reduced
pressure.
[0186] 0.43 g of
7-chloro-9-methyl-4-[(4-methylpiperazin-1-yl)carbonyl]-2-phenyl-9H-pyrimi-
do[4,5-b]indole were isolated in the form of a white solid.
[0187] M.P.: 236-238.degree. C.
[0188] LC/MS: M.sup.+H=420.
[0189] .sup.1H NMR (CDCl.sub.3, 200 MHz): 8.8 (m, 2H); 8.1 (d, 1H);
7.6-7.5 (m, 4H); 7.3 (dd, 1H); 4.1 (m, 2H); 4.0 (s, 3H); 3.6 (m,
2H); 2.7 (m, 2H); 2.5 (m, 2H); 2.4 (s, 3H).
EXAMPLE 12
Compound No. 21
2-(7-chloro-9-methyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indol-4-yl)-N,N-dime-
thylacetamide
12.1. Ethyl 2-amino-6-chloro-1-methyl-1H-indole-3-carboxylate
[0190] Under nitrogen, 2.5 g (62.5 mmol) of sodium hydride (at 60%
in mineral oil) were introduced into 200 ml of tetrahydrofuran. The
mixture was cooled to 0.degree. C. and 14.89 g (62.38 mmol) of
ethyl 2-amino-6-chloro-1H-indole-3-carboxylate were added in
portions. After stirring for 1 h at 0.degree. C., 3.9 ml (62.6
mmol) of iodo-methane were added and the mixture was stirred for 12
h at ambient temperature. 3 ml of absolute ethanol was added and
the mixture was concentrated under reduced pressure. The residue
was purified by chromatography on a silica gel column with a
mixture of solvents (dichloromethane/ethyl acetate: 98/2 to 80/20).
The fractions containing the compound were concentrated under
reduced pressure.
[0191] 5.9 g of ethyl
2-amino-6-chloro-1-methyl-1H-indol-3-carboxylate were isolated in
the form of a solid.
[0192] M.P.: 155-157.degree. C.
12.2.
7-chloro-9-methyl-2-pyridin-4-yl-3,9-dihydro-4H-pyrimido[4,5-b]indol-
-4-one
[0193] Under nitrogen, 0.32 g (8 mmol) of sodium hydride (at 60% in
mineral oil) were introduced into 100 ml of tetrahydrofuran. The
mixture was cooled to 0.degree. C. and 2.0 g (7.91 mmol) of ethyl
2-amino-6-chloro-1-methyl-1H-indole-3-carboxylate, obtained in step
12.1. from example 12 were added. After stirring for 40 minutes at
0.degree. C., the refrigerated bath was removed and 2 g (19.2 mmol)
of 4-cyanopyridine were added. Next, the mixture was stirred at
80.degree. C. for 18 h. The mixture was cooled to ambient
temperature then it was concentrated under reduced pressure. Added
to the residue were dichloromethane, water and a 1M aqueous
solution of sodium hydroxide. The mixture was stirred for 2 h. An
insoluble fraction was recovered by filtration, rinsed with water
and dried in an oven under reduced pressure and in the presence of
phosphorus pentoxide.
[0194] 1.55 g of
7-chloro-9-methyl-2-pyridin-4-yl-3,9-dihydro-4H-pyrimido[4,5-b]indol-4-on-
e were isolated in the form of a solid.
[0195] M.P.: >300.degree. C.
12.3.
4,7-dichloro-9-methyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indole
[0196] Under nitrogen and at 0.degree. C., 14 ml (160 mmol) of
oxalyl chloride were added slowly to 120 ml of
N,N-dimethylformamide. After stirring for 30 minutes, 1.55 g (5
mmol) of
7-chloro-9-methyl-2-pyridin-4-yl-3,9-dihydro-4H-pyrimido[4,5-b]indol-4-on-
e, obtained in step 12.2. of example 12 were added at 0.degree. C.
The refrigerated bath was removed and the mixture was heated to
80.degree. C. for 18 h. The mixture was cooled to room temperature
and poured over crushed ice. Next, dichloromethane and a 30%
aqueous solution of sodium hydroxide were added. After stirring,
the organic phase was decanted, washed with water, dried over
sodium sulfate, filtered and concentrated under reduced pressure.
The residue was partially dissolved in dichloromethane. The
insoluble fraction was separated by filtration and the filtrate was
purified by chromatography on a silica gel column with a mixture of
solvents (dichloromethane/ethyl acetate: 80/20 to 50/50). The
fractions containing the compound were combined with the insoluble
fraction, then they were partially concentrated under reduced
pressure. A precipitate was recovered by filtration that was then
rinsed with diethyl ether.
[0197] 0.83 g of
4,7-dichloro-9-methyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indole were
isolated in the form of a white solid.
[0198] M.P.: 272-274.degree. C.
12.4. Ethyl
2-(7-chloro-9-methyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indol-4-yl)-3-(dime-
thylamino)-3-oxopropanoate
[0199] Under nitrogen, 0.55 g (13.7 mmol) of sodium hydride (at 60%
in mineral oil) were introduced into 150 ml of 1,4-dioxane. The
mixture was cooled to 0.degree. C. and 2.2 g (13.8 mmol) of ethyl
3-(dimethylamino)-3-oxopropanoate were slowly added. After stirring
for 40 min at 0.degree. C., 0.83 g (2.52 mmol) of
4,7-dichloro-9-methyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indole,
obtained in step 12.3 from example 12, were added, then the
refrigerated bath was removed. Next, 2.5 g (13.1 mmol) of copper
iodide were added and the mixture was heated for 6 h under reflux.
The mixture was cooled to ambient temperature and concentrated
under reduced pressure. Next, dichloromethane, water and a
saturated aqueous solution of sodium hydrogen carbonate were added.
After stirring, the organic phase was decanted, washed with water,
dried over sodium sulfate, filtered and were concentrated under
reduced pressure. The residue was purified by chromatography on a
silica gel column with a mixture of solvents (ethyl
acetate/methanol: 100/0 to 90/10, then addition of 2% ammonia). The
fractions containing the compound were partially concentrated under
reduced pressure. A precipitate was isolated by filtration, rinsed
with diethyl ether and dried under reduced pressure.
[0200] 0.79 g of ethyl
2-(7-chloro-9-methyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indol-4-yl)-3-(dime-
thylamino)-3-oxopropanoate were isolated in the form of a yellowish
solid.
[0201] M.P.: 224-226.degree. C.
12.5.
2-(7-chloro-9-methyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indol-4-yl)-N,-
N-dimethylacetamide
[0202] Over 4 h at 50.degree. C., a solution of 0.79 g (1.85 mmol)
of ethyl
2-(7-chloro-9-methyl-2-pyridin-4-yl-9H-pyri-mido[4,5-b]indol-4-yl)--
3-(dimethylamino)-3-oxo-propanoate obtained in step 12.4 were
stirred with 1.4 g (33.3 mmol) of lithium hydroxide monohydrate in
a mixture of 10 ml of water, 50 ml of tetrahydrofuran and 50 ml of
methanol. The mixture was cooled to ambient temperature and
concentrated under reduced pressure. A solution of 35% hydrochloric
acid in water was slowly added and stirred for 5 min. Next, an
aqueous 30% sodium hydroxide solution was slowly added up to a
basic pH. Dichloromethane was added. The organic phase was
decanted. The aqueous phase was extracted with dichloromethane. The
organic phases were combined, washed with water, dried over sodium
sulfate, filtered and concentrated under reduced pressure. The
residue was purified by chromatography on a silica gel column with
a mixture of solvents (ethyl acetate/methanol: 100/0 to 90/10). The
fractions containing the compound were concentrated under reduced
pressure. The solid was recrystallized in an ethyl acetate/methanol
mixture, and rinsed with diethyl ether.
[0203] 0.19 g of
2-(7-chloro-9-methyl-2-pyridin-4-yl-9H-pyrimido[4,5-b]indol-4-yl)-N,N-dim-
ethylacetamide were isolated in the form of a white solid.
[0204] M.P.: 231-232.degree. C.
[0205] LC/MS: M.sup.+H=380.
[0206] .sup.1H NMR (DMSOd.sub.6, 200 MHz): 8.8 (m, 2H); 8.4 (m,
2H); 8.2 (d, 1H); 8.0 (d, 1H); 7.4 (dd, 1H); 4.5 (s, 2H); 4.0 (s,
3H); 3.2 (s, 3H); 2.9 (s, 3H).
EXAMPLE 13
Compound No 19
2-(7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indol-4-yl)-N,N-dimethylac-
etamide
13.1. 2,6-dichloro-1H-indole-3-carbaldehyde
[0207] Under nitrogen, 27 ml (292 mmol) of phosphorus oxychloride
were added dropwise at 0.degree. C. to 28 ml (366 mmol) of
N,N-dimethylformamide in 190 ml of dichloromethane. The mixture was
stirred for 2 h at ambient temperature. It was cooled to 0.degree.
C. and 24.5 g (146 mmol) of 6-chloro-1,3-dihydro-2H-indol-2-one
were added in small portions. The mixture was stirred for 4 h at
ambient temperature. It was cooled to 0.degree. C. and 12.7 ml (146
mmol) of oxalyl chloride were added. Next, it was stirred for 12 h
at ambient temperature. The mixture was cooled and 250 ml of water
were added. The organic phase was decanted and washed with water (3
times). A solid precipitated from the organic phase. It was
recovered by filtration and dried under reduced pressure in the
presence of phosphorus pentoxide. The aqueous phases were combined
and stirred for around 7 h. A solid precipitated from the aqueous
phase. It was recovered by filtration and it was also dried under
reduced pressure in the presence of phosphorus pentoxide. The two
precipitates were combined and 16 g of
2,6-dichloro-1H-indole-3-carbaldehyde were obtained in the form of
a white/beige solid.
[0208] .sup.1H NMR (DMSOd.sub.6, 200 MHz): 9.9 (s, 1H); 7.9 (d,
1H); 7.4 (s, 1H); 7.2 (d, 1H)
13.2. 2,6-dichloro-1-methyl-1H-indole-3-carbaldehyde
[0209] A solution of 11 g (52 mmol) of
2,6-dichloro-1H-indole-3-carbaldehyde, obtained in step 13.1, 14.7
ml (155 mmol) of dimethyl sulfate, 0.62 g (1.8 mmol) of
tetramethylammonium hydrogensulfate, 770 ml of dichloromethane and
27.4 g (258 mmol) of potassium carbonate in 120 ml of water were
stirred for 2 h under reflux. The mixture was cooled to ambient
temperature. The organic phase was decanted. The aqueous phase was
extracted with dichloromethane. The organic phases were combined
and washed with water then with a saturated aqueous solution of
sodium chloride. They were dried over sodium sulfate, filtered and
concentrated under reduced pressure. The residue was titrated in
diisopropyl ether. It was recovered by filtration and taken up in
dichloromethane with a little methanol. The insoluble fraction was
separated by filtration. The filtrate was partially concentrated. A
solid precipitated and was recovered by filtration. The insoluble
fraction and the solid were combined.
[0210] 8.5 g of 2,6-dichloro-1-methyl-1H-indole-3-carbaldehyde were
obtained in the form of a pale beige solid.
[0211] M.P.: 166-168.degree. C.
13.3. 2,6-dichloro-1-methyl-1H-indole-3-carboxylic acid
[0212] 10.5 g (46 mmol) of
2,6-dichloro-1-methyl-1H-indole-3-carbaldehyde, obtained according
to step 13.2. from example 13, was introduced into 180 ml of
dioxane and 45 ml of 2-methyl-2-butene. A solution of 20 g (221
mmol) of sodium chloride and 20 g (145 mmol) of monosodium
phosphate in 120 ml of water were slowly added. The mixture was
stirred for 2 h, then a solution of 5 g (55 mmol) of sodium
chloride and 5 g (36 mmol) of monosodium phosphate in 30 ml of
water were added. The mixture was stirred for 2 h, then a solution
of 3 g (33 mmol) of sodium chloride and 3 g (22 mmol) of monosodium
phosphate in 20 ml of water were added. The mixture was stirred for
3 h. 200 ml of ethyl acetate were added and it was left stirring
overnight. An insoluble fraction was recovered by filtration and
washed with water. The aqueous phase was extracted with ethyl
acetate. The organic phases were combined and extracted with 1 M
sodium hydroxide. The aqueous phase was cooled then acidified with
6 N hydrochloric acid up to a pH of 2-3. A solid precipitated. It
was recovered by filtration and washed with water. It was combined
with the insoluble fraction and they were dried under reduced
pressure in the presence of phosphorus pentoxide.
[0213] 8.7 g of 2,6-dichloro-1-methyl-1H-indole-3-carboxylic acid
were obtained in the form of a yellowish white solid.
[0214] M.P.: 243-245.degree. C.
13.4.
7-chloro-9-methyl-2-phenyl-3,9-dihydro-4H-pyrimido[4,5-b]indol-4-one
[0215] 12 g (49 mmol) of
2,6-dichloro-1-methyl-1H-indole-3-carboxylic acid, obtained
according to step 13.3. from example 13, were introduced into 170
ml of dioxane. 58 ml (790 mmol) of thionyl chloride were added
slowly and the mixture was heated to 70.degree. C. for 5 h. It was
cooled to ambient temperature and the mixture was concentrated
under reduced pressure. Toluene was added, then the mixture was
concentrated under reduced pressure (2 times). Next, 300 ml of
dioxane were added, the mixture was cooled to 0.degree. C. and a
solution of 25 g (208 mmol) of benzamidine in 200 ml of dioxane
were added rapidly. The mixture was stirred for 12 h at ambient
temperature. 50 ml of water and 300 ml of dichloromethane were
added. The organic phase was decanted, dried over sodium sulfate,
filtered and are concentrated under reduced pressure. 30 g of an
orange-colored oil was obtained. 15 g of this oil were taken and
added to 300 ml of diphenyl ether. The mixture was heated at
200.degree. C. for 4 h. It was cooled, and the insoluble fraction
was recovered by filtration and rinsed with diethyl ether. It was
poured into 400 ml of dioxane and heated under reflux. A solid was
recovered by hot filtration and was rinsed with dioxane. It was
dried under reduced pressure in the presence of phosphorus
pentoxide.
[0216] 6.5 g of
7-chloro-9-methyl-2-phenyl-3,9-dihydro-4H-pyrimido[4,5-b]indol-4-one
were obtained.
[0217] M.P.: >300.degree. C.
13.5.
4-bromo-7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole
[0218] A solution of 1.5 g (4.8 mmol) of
7-chloro-9-methyl-2-phenyl-3,9-dihydro-4H-pyrimido[4,5-b]indol-4-one,
obtained in step 13.4., in 150 ml of acetonitrile were heated under
reflux for 18 h in the presence of 4.0 g (13.9 mmol) of phosphorus
oxybromide and 2.0 g (14.5 mmol) of potassium carbonate. The
mixture was cooled to ambient temperature and the solution was
poured over crushed ice. Dichloromethane and a saturated aqueous
solution of potassium carbonate were added. The organic phase was
filtered over celite.TM., washed with water, dried over sodium
sulfate, filtered and concentrated under reduced pressure. The
residue is purified by chromatography on a silica gel column with a
mixture of solvents (cyclohexane/dichloromethane: 100/0 to 50/50).
The fractions containing the compound were concentrated under
reduced pressure.
[0219] 1.1 g of
4-bromo-7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole were
isolated in the form of a pinkish white solid.
[0220] .sup.1H NMR (CDCl.sub.3, 200 MHz): 8.5-8.4 (m, 2H); 8.3 (d,
1H); 7.5-7.2 (m, 5H); 3.9 (s, 3H).
13.6. Ethyl
2-(7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indol-4-yl)-3-(dimethylam-
ino)-3-oxopropanoate
[0221] 0.4 g (10 mmol) of sodium hydride (at 60% in mineral oil)
was washed with pentane, then 50 ml of 1,4-dioxane were added under
nitrogen. The mixture was cooled to 0.degree. C. and 1.5 g (9.4
mmol) of ethyl 3-(dimethylamino)-3-oxopropanoate were added
dropwise. The mixture was stirred for 30 min at ambient temperature
and 0.80 g (2.15 mmol) of
4-bromo-7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole,
obtained in step 13.5. and
[0222] 0.80 g (4.2 mmol) of copper iodide were added successively.
The solution was refluxed for 20 h. It was cooled to ambient
temperature and dichloromethane and water were added. The organic
phase was decanted, washed with water, dried over sodium sulfate,
filtered and concentrated under reduced pressure. The residue was
purified by chromatography on a silica gel column with a mixture of
solvents (dichloromethane/ethyl acetate: 100/0 to 95/5). The
fractions containing the compound were concentrated under reduced
pressure. The residue was dissolved in dichloromethane with ethyl
acetate. The mixture was partially concentrated until the
appearance of a precipitate. It was recovered by filtration and
rinsed with diethyl ether.
[0223] 1.03 g of ethyl
2-(7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indol-4-yl)-3-(dimethylam-
ino)-3-oxopropanoate containing a minor amount of
2-(7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indol-4-yl)-N,N-dimethyla-
cetamide were isolated in the form of a solid.
13.7.
2-(7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indol-4-yl)-N,N-dime-
thylacetamide
[0224] A solution of 1.03 g (2.3 mmol) of ethyl
2-(7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indol-4-yl)-3-(dimethylam-
ino)-3-oxopropanoate, obtained in step 13.6, 0.80 g (19 mmol) of
lithium hydroxide in a mixture of 30 ml of tetrahydrofuran, 30 ml
of methanol and 5 ml of water were heated at 50.degree. C. for 2 h.
The mixture was cooled to ambient temperature, then it was
concentrated under reduced pressure. Dichloromethane, water and a
1M aqueous solution of hydrochloric acid were added. The organic
phase was decanted, washed with water, dried over sodium sulfate,
filtered and concentrated under reduced pressure. The residue was
purified by chromatography on a silica gel column with a mixture of
solvents (dichloromethane/ethyl acetate: 100/0 to 95/5). The
fractions containing the compound were concentrated under reduced
pressure. The residue was recrystallized in a dichloromethane/ethyl
acetate mixture, it was recovered by filtration, rinsed with ethyl
ether and dried under reduced pressure in the presence of
phosphorus pentoxide.
[0225] 0.48 g of
2-(7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indol-4-yl)-N,N-dimethyla-
cetamide were isolated in the form of a white solid.
[0226] M.P.: 185-187.degree. C.
[0227] LC/MS: M.sup.+H=379.
[0228] .sup.1H NMR (CDCl.sub.3, 200 MHz): 8.6 (m, 2H); 8.3 (d, 1H);
7.5 (m, 4H); 7.4 (m, 1H); 4.4 (s, 2H); 4.0 (s, 3H); 3.3 (s, 3H);
3.0 (s, 3H).
EXAMPLE 14
Compound No 25
[0229] Methyl
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate
14.1. 7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]-indol-4-yl
trifluoromethanesulfonate
[0230] Under nitrogen and at 0.degree. C., 2.5 ml (14.56 mmol) of
trifluoromethane sulfonic anhydride were added dropwise to a
solution of 3.0 g (9.7 mmol) of
7-chloro-9-methyl-2-phenyl-3,9-dihydro-4H-pyrimido[4,5-b]indol-4-one,
obtained in step 13.4. from example 13 and 4.3 ml (38.8 mmol) of
pyridine in 100 ml of dichloromethane. The mixture was stirred for
15 min at 0.degree. C., then 4 h at ambient temperature.
Dichloromethane, water and a 0.1 N hydrochloric acid solution were
added. The organic phase was decanted, the aqueous phase was
extracted with dichloromethane. The organic phases were combined.
They were dried over sodium sulfate, filtered, and concentrated
under reduced pressure.
[0231] 3.9 g of
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indol-4-yl
trifluoromethanesulfonate were obtained in the form of a yellowish
white solid that was used as such in the following step.
14.2. Methyl
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate
[0232] A solution of 2.5 g (5.7 mmol) of
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indol-4-yl
trifluoromethane-sulfonate, obtained in step 14.1. from example 14,
2.2 ml (14.8 mmol) of triethylamine, 30 mg (0.13 mmol) of palladium
acetate, 90 mg (0.22 mmol) of 1,3-bis(diphenylphosphino)propane in
45 ml of N,N-dimethylformamide and 19 ml of methanol were heated at
70.degree. C. under a carbon monoxide atmosphere. The solution was
cooled, and the insoluble fraction was filtered and rinsed with
dichloromethane. The filtrate was concentrated under reduced
pressure, then it was co-evaporated with toluene under reduced
pressure. Dichloromethane and water were added to the residue. The
organic phase was dried over sodium sulfate, filtered and
concentrated under reduced pressure. The residue was purified by
chromatography on a silica gel column with a mixture of solvents
(cyclohexane/dichloromethane:50/50 to 0/100). The fractions
containing the compound were concentrated under reduced
pressure.
[0233] 0.58 g
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]-indole-4-carboxylate
were isolated in the form of a white solid.
[0234] M.P.: 192-193.degree. C.
[0235] .sup.1H NMR (CDCl.sub.3, 200 MHz): 8.7 (d, 1H); 8.6 (m, 2H);
7.5-7.4 (m, 4H); 7.3 (dd, 1H); 4.1 (s, 3H); 3.9 (s, 3H).
EXAMPLE 15
Compound No 26
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylic
acid
[0236] A solution of 0.57 g (1.62 mmol) of
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate,
obtained in step 14.2 from example 14 and 300 mg (7.1 mmol) of
lithium hydroxide monohydrate in a mixture of 50 ml of
tetrahydrofuran, 20 ml of methanol and 10 ml of water were stirred
for 12 h at ambient temperature. A solution of 1 N hydrochloric
acid was added up to a pH of around 1. The organic solvents were
removed under reduced pressure and the precipitate obtained was
recovered by filtration. It was rinsed with water then with diethyl
ether and dried under reduced pressure in the presence of
phosphorus pentoxide.
[0237] 0.5 g of
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylic
acid were isolated in the form of a white solid.
[0238] M.P.: 208-209.degree. C.
[0239] .sup.1H NMR (DMSOd.sub.6, 200 MHz): 8.6-8.4 (m, 3H); 7.8 (d,
1H); 7.5-7.4 (m, 3H); 7.3 (dd, 1H); 3.9 (s, 3H).
EXAMPLE 16
Compound No 2
7-chloro-N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide
[0240] A solution of 0.60 g (1.8 mmol) of
7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylic
acid, obtained according to example 15, and 0.45 g (2.7 mmol) of
carbonyldiimidazole in 100 ml of tetrahydrofuran were heated at
70.degree. C. under a nitrogen atmosphere for 3 h. The mixture was
cooled to ambient temperature and the reaction medium was saturated
with gaseous dimethylamine until a basic pH was obtained, then it
was stirred for 12 h at ambient temperature. The solution was
concentrated under reduced pressure. Next, dichloromethane and a
0.5 N hydrochloric acid solution were added. The organic phase was
washed with a saturated aqueous solution of sodium chloride, dried
over sodium sulfate, filtered and concentrated under reduced
pressure. The residue was purified by chromatography on a silica
gel column with a mixture of solvents (dichloromethane/methanol:
100/0 to 95/5). The fractions containing the compound were
concentrated under reduced pressure. The solid was recrystallized
in ethyl acetate and rinsed with diethyl ether.
[0241] 0.33 g of
7-chloro-N,N,9-trimethyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxamide
were isolated in the form of a white solid.
[0242] M.P.: 211-213.degree. C.
[0243] LC/MS: M+H=365.
[0244] .sup.1H NMR (CDCl.sub.3, 200 MHz): 8.7 (m, 2H); 8.1 (d, 1H);
8.6-8.5 (m, 4H); 7.3 (dd, 1H); 4.0 (s, 3H); 3.4 (s, 3H); 3.1 (s,
3H).
EXAMPLE 17
Compound No 28
7-chloro-2-(6-methoxypyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indol-
e-4-carboxamide
[0245] A solution of 490 mg (3.24 mmol) of
6-methoxypyridine-3-carboxamidine and 300 mg (1.0 mmol) of
2-(2,6-dichloro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,
obtained in step 1.2. from example 1, in 7 ml of
N,N-dimethylformamide was heated at 130.degree. C. for 2 h. The
solution was cooled. The precipitate was recovered by filtration,
it was rinsed with 1,4-dioxane and dried under reduced pressure. It
was purified by chromatography on a silica gel column with a
mixture of solvents (dichloromethane/methanol:97/3). The compound
obtained was recrystallized in an ethyl acetate/methanol mixture,
filtered, rinsed with diethyl ether and dried under reduced
pressure.
[0246] 0.22 g of
7-chloro-2-(6-methoxypyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indo-
le-4-carboxamide were isolated in the form of a white solid.
[0247] M.P.: 267-268.degree. C.
[0248] LC/MS: M+H=396.
[0249] .sup.1H NMR (CDCl.sub.3, 200 MHz): 9.45 (d, 1H); 8.75 (dd,
1H); 8.05 (d, 1H); 7.5 (d, 1H); 7.25 (dd, 1H); 6.85 (d, 1H); 4.05
(s, 3H); 4.0 (s, 3H); 3.35 (s, 3H); 3.1 (s, 3H).
EXAMPLE 18
Compound No 41
7-chloro-2-(5-ethylpyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indole--
4-carboxamide
[0250] A solution of 820 mg (5.50 mmol) of
5-ethylpyridin-3-carboxamidine and 400 mg (1.34 mmol) of
2-(2,6-dichloro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,
obtained in step 1.2 from example 1, in 30 ml of
N,N-dimethylformamide was heated at 130.degree. C. for 3 h. The
solution was cooled. The reaction mixture was concentrated under
reduced pressure. Dichloromethane was added and it was washed with
water. The organic phase was dried over sodium sulfate. The mixture
was filtered and concentrated under reduced pressure. The residue
was purified by chromatography on a silica gel column with a
mixture of solvents (dichloromethane/ethyl acetate: 90/10 to 80/20,
then ethyl acetate/methanol: 100/0 to 95/5). The compound obtained
was recrystallized in a dichloromethane/ethyl acetate mixture,
filtered, rinsed with ethyl acetate and dried under reduced
pressure.
[0251] 0.18 g of
7-chloro-2-(5-ethylpyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indole-
-4-carboxamide were isolated in the form of a pale yellow
solid.
[0252] M.P.: 218-219.degree. C.
[0253] LC/MS: M.sup.+H=394.
[0254] .sup.1H NMR (CDCl.sub.3, 200 MHz): 9.45 (d, 1H); 8.60 (m,
2H); 7.95 (d, 1H); 7.90 (d, 1H): 7.4 (dd, 1H); 4.0 (s, 3H); 3.30
(s, 3H); 3.20 (s, 3H); 2.95 (s, 3H); 2.80 (q, 2H); 1.25 (t,
3H).
EXAMPLE 19
Compound No 48
5-(7-chloro-4-dimethylcarbamoyl-9-methyl-9H-pyrimido[4,5-b]indol-2-yl)-2,3-
-dimethyl-pyridinium chloride
[0255] A solution of 930 mg (6.23 mmol) of
5,6-dimethylpyridine-3-carboxamidine and 600 mg (2.01 mmol) of
2-(2,6-dichloro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,
obtained in step 1.2. from example 1, in 50 ml of o-xylene was
heated under reflux for 5 h. The solution was cooled. The reaction
mixture was concentrated under reduced pressure. Dichloromethane
and a saturated aqueous solution of sodium bicarbonate were added.
The organic phase was washed with water and dried over sodium
sulfate. It was filtered and the filtrate was concentrated under
reduced pressure. The residue was purified by chromatography on a
silica gel column with a mixture of solvents (dichloromethane/ethyl
acetate: from 80/20 to 0/100, then ethyl acetate/methanol: 100/0 to
95/5). After evaporation of the solvents, 340 mg (0.86 mmol) of a
white solid was recovered. It was dissolved in dichloromethane and
0.35 ml (1.73 mmol) of a 5-6 N hydrochloric acid solution in
isopropanol were added. The solvents were evaporated under reduced
pressure and the residue was recrystallized in absolute ethanol. It
was filtered, rinsed with diethyl ether and dried under reduced
pressure.
[0256] 0.30 g of
5-(7-chloro-4-dimethylcarbamoyl-9-methyl-9H-pyrimido[4,5-b]indol-2-yl)-2,-
3-dimethyl-pyridinium chloride were isolated.
[0257] M.P.: 285-289.degree. C.
[0258] LC/MS: M.sup.+H=394.
[0259] .sup.1H NMR (CDCl.sub.3, 200 MHz): 9.4 (s, 1H); 9.05 (s,
1H); 8.0 (d, 1H); 7.90 (d, 1H); 7.45 (dd, 1H); 4.05 (s, 3H); 3.20
(s, 3H); 2.95 (s, 3H); 2.70 (s, 3H); 2.50 (s, 3H).
EXAMPLE 20
Compound No 49
3-(7-chloro-4-dimethylcarbamoyl-9-methyl-9H-pyrimido[4,5-b]indol-2-yl)-5,6-
,7,8-tetrahydro-quinolinium chloride
[0260] A solution of 2.40 g (13.7 mmol) of
5,6,7,8-tetrahydroquinoline-3-carboxamidine and 800 mg (2.67 mmol)
of
2-(2,6-dichloro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,
obtained in step 1.2 from example 1, in 70 ml of o-xylene was
heated under reflux for 5 h. The solution was cooled. The reaction
mixture was concentrated under reduced pressure. Dichloromethane
and a saturated aqueous solution of sodium bicarbonate were added.
The organic phase was washed with water, and dried over sodium
sulfate. It was filtered and the filtrate was concentrated under
reduced pressure. The residue was purified by chromatography on a
silica gel column with a mixture of solvents (dichloromethane/ethyl
acetate: from 90/10 to 0/100). After evaporation of the solvents,
870 mg (2.07 mmol) of a white solid was recovered. It was dissolved
in dichloromethane and 0.83 ml (4.14 mmol) of a 5-6 N hydrochloric
acid solution in isopropanol were added. The solvents were
evaporated under reduced pressure and the residue was
recrystallized in absolute ethanol. It was filtered, rinsed with
diethyl ether and dried under reduced pressure.
[0261] 0.75 g of
3-(7-chloro-4-dimethylcarbamoyl-9-methyl-9H-pyrimido[4,5-b]indol-2-yl)-5,-
6,7,8-tetrahydro-quinolinium chloride were isolated.
[0262] M.P.: 289-291.degree. C.
[0263] LC/MS: M.sup.+H=420.
[0264] .sup.1H NMR (CDCl.sub.3, 200 MHz): 9.35 (s, 1H); 8.60 (s,
1H); 7.90 (d, 1H); 7.85 (d, 1H); 7.35 (dd, 1H); 4.00 (s, 3H); 3.20
(s, 3H); 2.95-2.80 (m, 7H); 1.95-1.65 (m, 4H).
EXAMPLE 21
Compound No 50
4-(7-chloro-4-dimethylcarbamoyl-9-methyl-9H-pyrimido[4,5-b]indol-2-yl)-2,6-
-dimethylpyridinium chloride
[0265] A solution of 0.78 g (5.23 mmol) of
2,6-dimethylpyridine-4-carboxamidine and 700 mg (2.34 mmol) of
2-(2,6-dichloro-1-methyl-1H-indol-3-yl)-N,N-di-methyl-2-oxoacetamide,
obtained in step 1.2 from example 1, in 30 ml of o-xylene was
heated under reflux for 5 h. The solution was cooled. The reaction
mixture was concentrated under reduced pressure. Dichloromethane,
water and a 1 M aqueous solution of sodium hydroxide were added.
The organic phase was washed with water, and dried over sodium
sulfate. It was filtered and the filtrate was concentrated under
reduced pressure. The residue was purified by chromatography on a
silica gel column with a mixture of solvents (dichloromethane/ethyl
acetate: from 80/20 to 0/100, then ethyl acetate/methanol: 100/0 to
95/5). After evaporation of the solvents, 540 mg (1.37 mmol) of a
white solid was recovered. It was dissolved in dichloromethane and
0.55 ml (2.74 mmol) of a 5.6 N hydrochloric acid solution in
isopropanol were added. The solvents were evaporated under reduced
pressure and the residue was recrystallized in absolute ethanol. It
was filtered, rinsed with diethyl ether and dried under reduced
pressure.
[0266] 0.69 g of
4-(7-chloro-4-dimethylcarbamoyl-9-methyl-9H-pyrimido[4,5-b]indol-2-yl)-2,-
6-dimethylpyridinium chloride were isolated.
[0267] M.P.: 288-292.degree. C.
[0268] LC/MS: M.sup.+H=394.
[0269] .sup.1H NMR (CDCl.sub.3, 200 MHz): 8.50 (s, 2H); 8.00 (d,
1H); 7.95 (d, 1H); 7.45 (dd, 1H); 4.05 (s, 3H); 3.20 (s, 3H); 2.95
(s, 3H); 2.75 (s, 6H).
[0270] Table 1 below illustrates the chemical structures and the
physical properties of some compounds of the invention.
[0271] In the "salt" column of this table, "-" represents a
compound in free base form, whereas "HCl" represents a compound in
hydrochloride form and the ratio between brackets is the acid/base
ratio.
TABLE-US-00001 TABLE 1 (I) ##STR00006## No. n X Y R.sub.1 R.sub.2
Salt M.P. (.degree. C.) 1 0 H N(CH.sub.3).sub.2 CH.sub.3 phenyl --
193-195 2 0 7-Cl N(CH.sub.3).sub.2 CH.sub.3 phenyl -- 211-213 3 0
7-F N(CH.sub.3).sub.2 CH.sub.3 phenyl -- 229-231 4 0 6-Cl
N(CH.sub.3).sub.2 CH.sub.3 phenyl -- 222-224 5 0 7-Cl
N(CH.sub.3).sub.2 H phenyl -- 232-233 6 0 7-Cl
N(CH.sub.2CH.sub.3).sub.2 CH.sub.3 phenyl -- 174-176 7 0 7-Cl
pyrrolidin-1-yl CH.sub.3 phenyl -- 210-212 8 0 7-Cl piperidin-1-yl
CH.sub.3 phenyl -- 216-218 9 0 7-Cl morpholin-1-yl CH.sub.3 phenyl
-- 214-216 10 0 7-Cl 4-(N- CH.sub.3 phenyl -- 248-249 azetidinyl)
piperidin-1-yl 11 0 7-Cl N- CH.sub.3 phenyl -- 236-238
methylpiperazin 1-yl 12 0 6-Cl N(CH.sub.3).sub.2 CH.sub.3
pyridin-4-yl -- 226-227 13 0 7-F N(CH.sub.3).sub.2 CH.sub.3
pyridin-4-yl -- 272-274 14 0 7-Cl pyrrolidin-1-yl CH.sub.3
pyridin-4-yl -- 256-258 15 0 7-Cl N(CH.sub.3).sub.2 CH.sub.3
pyridin-4-yl -- 268-269 16 0 7-Cl N(CH.sub.3).sub.2 CH.sub.3
pyridin-3-yl -- 283-284 17 0 7-Cl N(CH.sub.3).sub.2 CH.sub.3
pyridin-2-yl -- 233-235 18 0 7-Cl N(CH.sub.3).sub.2 CH.sub.3
pyrazin-2-yl -- 272-273 19 1 7-Cl N(CH.sub.3).sub.2 CH.sub.3 phenyl
-- 185-187 20 1 6-Cl N(CH.sub.3).sub.2 CH.sub.3 phenyl -- 234-236
21 1 7-Cl N(CH.sub.3).sub.2 CH.sub.3 pyridin-4-yl -- 231-232 22 1
7-Cl N(CH.sub.3).sub.2 CH.sub.3 pyridin-3-yl -- 248-251 23 0 H
N(CH.sub.3).sub.2 H phenyl -- 218-219 24 0 7-Cl O(CH.sub.2CH.sub.3)
CH.sub.3 phenyl -- 139-140 25 0 7-Cl OCH.sub.3 CH.sub.3 phenyl --
192-193 26 0 7-Cl OH CH.sub.3 phenyl -- 208-209 27 0 7-Cl
N(CH.sub.3).sub.2 CH.sub.3 6-methylpyridin-3-yl -- 276-277 28 0
7-Cl N(CH.sub.3).sub.2 CH.sub.3 6-methoxypyridin-3-yl -- 267-268 29
0 7-Cl N(CH.sub.3).sub.2 CH.sub.3 2-methylpyridin-4-yl -- 242-244
30 0 7-Cl N(CH.sub.3).sub.2 CH.sub.3 2-methoxy-pyridin-4- --
278-279 yl 31 0 7-Cl N(CH.sub.3).sub.2 Isobutyl pyridin-4-yl HCl
230-236 (1/1) 32 0 7-Cl N(CH.sub.3).sub.2 CH.sub.3 cyclopropyl --
197-198 33 0 7-Cl N(CH.sub.3).sub.2 CH.sub.3 methyl -- 193-195 34 0
7-Cl N(CH.sub.3).sub.2 CH.sub.3 isopropyl -- 125-126 35 0 7-Cl
N(CH.sub.3).sub.2 CH.sub.3 tetrahydro-2H-pyran- -- 174.5- 4-yl
175.5 36 0 7-Cl N(CH.sub.3).sub.2 CH.sub.3 4- HCl 257-258
[(dimethylamino)methyl] (1/1) phenyl 37 0 7-Cl N(CH.sub.3).sub.2
CH.sub.3 6-chloropyridin-3-yl -- 275-276 38 0 7-Cl
N(CH.sub.3).sub.2 CH.sub.3 6- (trifluoromethyl) -- 253-255
pyridin-3-yl 39 0 7-Cl N(CH.sub.3).sub.2 CH.sub.3
6-ethoxypyridin-3-yl -- 237-239 40 0 7-Cl N(CH.sub.3).sub.2
CH.sub.3 6-ethylpyridin-3-yl -- 232-235 41 0 7-Cl N(CH.sub.3).sub.2
CH.sub.3 5-ethylpyridin-3-yl -- 218-219 42 0 7-Cl N(CH.sub.3).sub.2
CH.sub.3 5-methylpyridin-3-yl -- 313-314 43 0 7-Cl
N(CH.sub.3).sub.2 CH.sub.3 pyrimidin-5-yl -- 322-325 44 0 7-Cl
N(CH.sub.3).sub.2 CH.sub.3 5-methoxypyridin-3-yl -- 258-260 45 0
7-Cl N(CH.sub.3).sub.2 CH.sub.3 6- 0 N(CH.sub.3).sub.2
(methoxymethyl) -- 239-241 n-3-yl 46 0 7-Cl N(CH.sub.3).sub.2
CH.sub.3 2-methyl-1,3-thiazol- -- 256-258 4-yl 47 0 7-Cl
N(CH.sub.3).sub.2 CH.sub.3 6- HCl 240-242 [(dimethylamino) (1/1)
methyl] pyridin-3-yl 48 0 7-Cl N(CH.sub.3).sub.2 CH.sub.3
5,6-dimethylpyridin- HCl 285-289 3yl (1/1) 49 0 7-Cl
N(CH.sub.3).sub.2 CH.sub.3 5,6,7,8 HCl tetrahydroquinolin-3- (1/1)
289-291 yl 50 0 7-Cl N(CH.sub.3).sub.2 CH.sub.3
2,6-dimethylpyridin- HCl 4-yl (1/1) 288-292
[0272] The compounds of the invention were subjected to
pharmacological tests which demonstrated their advantage as
substances having therapeutic activities.
A Study of the Binding of [.sup.3H]Ro5-4864 to peripheral
benzodiazepine receptors (p or PBR sites)
[0273] The affinity of the compounds of the invention for the p or
PBR sites (sites of peripheral-type binding to benzodiazepines) was
determined.
[0274] The p site receptors can be labeled selectively in rat
kidney membranes incubated in the presence of [.sup.3H]Ro5-4864.
The compounds of the invention have been the subject of an in vitro
study with respect to their affinity for these receptors.
[0275] The animals used were male Sprague Dawley rats (Iffa Credo)
weighing 180 to 300 mg. After decapitation, the kidney was removed
and the tissue was homogenized at 4.degree. C. using a Polytron.TM.
homogenizer for 2 min and 6/10 of the maximum speed, in 35 volumes
of 50 mM Na.sub.2HPO.sub.4 phosphate buffer, at a pH adjusted to
7.5 with NaH.sub.2PO.sub.4. The membrane homogenate was filtered
over gaze and diluted 10 times with buffer.
[0276] [.sup.3H]Ro5-4864 (specific activity: 70-90 Ci/mmol; New
England Nuclear), at a concentration of 0.5 nM, was incubated in
the presence of 100 .mu.l of the membrane homogenate in a final
volume of 1 ml of buffer containing the compound to be tested.
[0277] After an incubation of 3 h at 0.degree. C., the membranes
were recovered by filtering over Whatman GF/B.TM. filters washed
with 2 times 4.5 ml of cold (0.degree. C.) incubation buffer. The
amount of radioactivity retained by the filter was measured by
liquid scintigraphy.
[0278] For each compound concentration studied, the percentage
inhibition of the binding of [.sup.3H]Ro5-4864, then IC.sub.50
concentration, the concentration which inhibits 50% of the specific
binding, were determined.
[0279] The IC.sub.50 of the most active compounds of the invention
had values ranging from 1 nM to 200 nM.
[0280] Table 2 below presents the IC.sub.50 values of some
compounds according to the invention.
TABLE-US-00002 TABLE 2 Compound No. IC.sub.50 2 2.2 nM 15 3.1 nM 19
1.3 nM
[0281] The compounds of the invention were therefore ligands with
an affinity for peripheral-type benzodiazepine receptors.
Study of the Neurotrophic Activity
[0282] Test of Survival of the Motor Neurons after Sectioning the
Facial Nerve in Rats Aged 4 Days
[0283] After lesion of the facial nerve in immature rats, the motor
neurons of the facial nucleus underwent neuronal death by
apoptosis. Neural survival was evaluated using histological methods
and neuronal counting.
[0284] 4 day old immature rats were anesthetized with pentobarbital
(3 mg/kg by the i.p. route). The right facial nerve was exposed and
sectioned, at its outlet from the stylomastoid foramen. After
waking up, the young rats were returned to their mothers and
treated for 7 days with one or two daily administrations, via oral
or intraperitoneal route, at doses ranging from 1 to 10 mg/kg.
[0285] 7 days after the lesion, the animals were decapitated and
the brains frozen in isopentane at -40.degree. C. The entire facial
nerve was cut with a cryostat into 10 .mu.m sections. The motor
neurons were colored with cresyl violet and counted using the
Histo.TM. software (Biocom.TM.).
[0286] In this model, the most active compounds of the invention
increased neuronal survival by about 10 to 40%.
[0287] Table 3 below presents the results for some compounds
according to the invention in this model.
TABLE-US-00003 TABLE 3 Compound No % 2 +25* 15 +40* 19 +21* *via
oral route, at 10 mg/kg
[0288] The results of the tests show that the most active compounds
of the invention promote nerve regeneration.
[0289] The compounds of the invention may therefore be used for
preparing medications intended to prevent or treat a pathology in
which the peripheral-type benzodiazepine receptors are
involved.
[0290] These medications find their application in therapeutics,
especially in the treatment and/or prevention of peripheral
neuropathies of various types, such as traumatic or ischemic
neuropathies, diabetic, infectious, alcoholic, medicinal or genetic
neuropathies, and also motor neurone diseases, such as spinal
amyotrophies and amyotrophic lateral sclerosis. These medications
also find an application in the treatment of neurodegenerative
diseases of the central nervous system, either of the acute type
such as cerebrovascular accidents and cranial and medular traumas,
or of the chronic type such as autoimmune diseases (multiple
sclerosis), Alzheimer's disease, Parkinson's disease and any other
disease in which the administration of neurotrophic factors has a
therapeutic effect.
[0291] The compounds of the invention may also be used for
preparing medications intended for the prevention and/or treatment
of anxiety, epilepsy or sleep disorders. This is because ligands of
the p or PBR sites stimulate the production of neurosteroids such
as pregnenolone, dehydroepiandrosterone, and
3-.alpha.-hydroxy-5-.alpha.-pregnan-20-one, by promoting the
transfer of cholesterol from the outside to the inside of the
mitochondrial membrane. These neurosteroids modulate the activity
of the GABAA-chloride channel macromolecular complex and can thus
produce anxiolytic, anticonvulsant and sedative activities.
[0292] The compounds of the invention may also be used in
treatments for acute or chronic renal failure, glomerulonephritis,
diabetic nephropathy, cardiac ischemia and heart failure,
myocardial infarction, ischemia of the lower limbs, coronary
vasospasm, angina poitrineous, pathologies associated with the
heart valves, inflammatory heart diseases, secondary effects due to
cardiotoxic medication or as a result of heart surgery,
atherosclerosis and its thromboembolic complications, restenosis,
graft rejections, conditions related to an incorrect proliferation
or migration of smooth muscle cells.
[0293] Furthermore, recent data from the literature indicates that
the peripheral-type benzodiazepine receptor could play a
fundamental role in the regulation of cell proliferation and
cancerization processes. Generally, and in comparison with normal
tissues, an increased density of peripheral-type benzodiazepine
receptors is observed in various types of tumors and cancers.
[0294] In human astrocytomas, the expression level of the
peripheral-type benzodiazepine receptor is correlated with the
degree of malignicy of the tumor, the proliferation index and the
survival of the patients. In human cerebral tumors, the increase of
the number of peripheral-type benzodiazepine receptors is used as a
diagnostic indication in medical imaging and as a therapeutic
target for conjugates formed from a ligand of the peripheral-type
benzodiazepine receptor and from a cytostatic drug. A high density
of peripheral-type benzodiazepine receptors is also observed in
ovarian carcinomas and breast cancers. Regarding the latter, it has
been demonstrated that the expression level of the peripheral-type
benzodiazepine receptors is linked to the aggressive potential of
the tumor; furthermore, the presence of a peripheral-type
benzodiazepine receptor agonist stimulates the growth of a mammary
cancer line.
[0295] The combination of these results, which suggests a
deleterious function of the peripheral-type benzodiazepine receptor
in cancerization processes, constitutes a relevant basis for the
search for synthetic ligands specific for the peripheral-type
benzodiazepine receptor which are capable of blocking the effects
thereof.
[0296] The compounds may therefore be used for treating tumors and
cancers.
[0297] The peripheral-type benzodiazepine receptors are also
present in the skin and, in this respect, the compounds that can be
used according to the invention may be used for the prophylaxis or
treatment of cutaneous stress.
[0298] The term "cutaneous stress" is understood to mean the
various situations which might cause damage, in particular to the
epidermis, regardless of the agent which causes this stress. This
agent can be internal and/or external to the body, such as a
chemical or radical agent, or else external such as ultraviolet
radiation.
[0299] Thus the compounds that can be used according to the
invention are intended to prevent and combat cutaneous irritations,
dry patches, erythemas, dysesthetic sensations, heating sensations,
pruritus of the skin and/or mucous membranes, or aging and may also
be used in cutaneous disorders such as, for example, psoriasis,
pruriginous diseases, herpes, photodermatoses, atopic dermatitis,
contact dermatitis, lichens, prurigo, pruritus, insect stings, in
fibroses and other disorders of collagen maturation, in
immunological disorders or else in dermatological conditions such
as eczema.
[0300] The compounds of the invention may also be used for
preventing and treating chronic inflammatory diseases, especially
rheumatoid arthritis, and pulmonary inflammatory diseases, in
particular asthma, acute respiratory distress syndrome (ARDS) and
chronic obstructive pulmonary disease (COPD), cystic fibrosis,
bronchopulmonary diseases, lung diseases and pulmonary
fibrosis).
[0301] According to one of its aspects, a subject of the invention
is medication which comprises a compound of formula (I), or a
pharmaceutically acceptable acid addition salt of the latter, or
else a hydrate or a solvate.
[0302] According to another of its aspects, the present invention
relates to pharmaceutical compositions comprising, as an active
principle, a compound according to the invention. These
pharmaceutical compositions contain an effective dose of at least
one compound according to the invention, or one pharmaceutically
acceptable salt, hydrate or solvate of said compound, and also to
at least one pharmaceutically acceptable excipient.
[0303] Said excipients are chosen according to the pharmaceutical
form and the method of administration desired, among the common
excipients which are known to a person skilled in the art.
[0304] In the pharmaceutical compositions of the present invention
for oral, sublingual, subcutaneous, intramuscular, intravenous,
topical, local, intratracheal, intranasal, transdermal or rectal
administration, the active principle of formula (I) above, or its
possible salt, solvate or hydrate, may be administered in unit
administration form, by mixing with conventional pharmaceutical
excipients, to animals and to humans for the prophylaxis or
treatment of the above disorders or diseases.
[0305] Suitable unit administration forms comprise forms via oral
route such as tablets, soft or hard gelatin capsules, powders,
granules and oral solutions or suspensions, sublingual, buccal,
intratracheal, intraocular or intranasal forms of administration,
via inhalation, topical, transdermal, subcutaneous, intramuscular
or intravenous forms of administration, rectal forms of
administration and implants. For topical application, it is
possible to use the compounds according to the invention in creams,
gels, pomades or lotions.
[0306] By way of example, a unit administration form of a compound
according to the invention in a form of a tablet may comprise the
following components:
TABLE-US-00004 Compound according to the invention 50.0 mg Mannitol
223.75 mg Sodium croscarmellose 6.0 mg Maize starch 15.0 mg
Hydroxypropyl methyl cellulose 2.25 mg Magnesium stearate 3.0
mg
[0307] Said unit forms are dosed in order to allow a daily
administration of 0.001 to 20 mg of active principle per kg of body
weight, depending on the pharmaceutical form.
[0308] There could be particular cases where higher or lower doses
are appropriate; such doses are not outside the scope of the
invention. According to common practice, the appropriate dose for
each patient is determined by the doctor depending on the mode of
administration, the weight and the response of said patient.
[0309] The present invention, according to another of its aspects,
also relates to a method of treating the pathologies indicated
above which comprise the administration, to a patient, of an
effective dose of a compound according to the invention, or one of
its pharmaceutically acceptable salts or hydrates or solvates.
* * * * *